Method for improving heterologous synthesis of Escherichia coli into polyketides and use of same

Description

TECHNICAL FIELD

The present invention falls within the fields of synthetic biology and industrial biotechnology, in particular, the present invention relates to a method for improving the heterologous synthesis of a polyketide by E. coli and use thereof.

BACKGROUND ART

Natural products play an important role in the process of drug development and discovery. Over the past decade, researchers have used natural products heterologously synthesized and the products have shown great potential. The heterologous biosynthesis of polyketids is one of the branches researched deeply and progressed rapidly in the current field of synthetic biology. Donadio proposed a synthetic model of 6-deoxyerythromycin lactone B in 1991, and studies on erythromycin polyketide synthases (PKSs) have thus become a paradigm for Type I PKSs. The biosynthesis of erythromycin is divided into two parts: the first is the formation of 6-deoxyerythronolide-B (6-dEB), the parent nucleus of erythromycin; and the second is the sidechain glycosylation of 6-dEB to synthesize erythromycin. 6-dEB is the first intermediate that can be isolated during the synthesis of erythromycin, and the starting materials for the synthesis of 6-dEB are propionic acid and methylmalonic acid. The entire process is catalyzed by polyketide synthases. Engineering ideas promote researchers to construct an engineered strain for the heterologous synthesis of natural products. As the metabolic network of E. coli has been researched most deeply, E. coli is often used as the chassis cell for engineered strains.

In 2001, Pfeifer et al. heterologously synthesized 6-dEB, the first precursor of erythromycin, using E. coli, opening the first line of the heterologous biosynthesis of erythromycin. Later researchers have also made many attempts to obtain erythromycin efficiently through E. coli, for example, in order to improve plasmid stability, Murli et al., in 2003, obtained an engineered strain K207-3/pKOS207-129/pBP130, with 22.5 mg/L of 6-dEB being obtained by culturing the same in a shake flask, by modifying pBP144 to pKOS207-129 through integrating genes pccB and pccA into the YgfG site encoding methylmalonyl-CoA decarboxylase in E. coli and replacing the starting site of pET28a derived from pBR322 with the replication origin of RSF1010. In order to improve the stability of the host itself, WANG Yong et al. obtained a chromosome-modified stable strain by integrating erythromycin polyketide synthase genes eryAI, AII and AIII into the chromosome of E. coli through a chromosome recombination Red/ET method, wherein the strain may stably synthesize 6-dEB, an intermediate of erythromycin, compared with the co-expression of multiple plasmids.

Over the recent decade, the heterologous synthesis of polyketids with erythromycin as the representative in E. coli has made a series of significant progresses, and erythromycin A was successfully synthesized in E. coli. However, there are still many problems, for example, the yield of erythromycin in E. coli is too low, compared with the original strain, Saccharopolyspora erythraea. MENG Hailin et al., in 2011, found that the actual yield of polyketids synthesized by E. coli was only about 1/10 of the theoretical yield currently after analyzing the metabolic network of E. coli using an in silico analysis and research platform, indicating that the heterogeneous synthetic pathway of polyketids is regulated by the global network of E. coli. Therefore, by modifying the global network of E. coli, it is possible to further improve its ability to heterologously synthesize polyketids.

SUMMARY OF THE INVENTION

An object of the present invention is to provide a method for improving the heterologous synthesis of a polyketide by E. coli and use thereof.

In a first aspect of the present invention, provided is a method for promoting a host strain for synthesizing the polyketide 6-deoxyerythronolide to synthesize the polyketide 6-deoxyerythronolide biologically, the method comprising:

(1) attenuating the expression of a target gene in the host strain for synthesizing the polyketide 6-deoxyerythronolide;

wherein, the target gene is selected from:

(a) a gene for nucleotide synthesis and other metabolism modules, purT, lsrC, hemN, zwf, pgl, gnd, rpe, talA, talB, tktA, tktB, ulaE or yieK;

(b) a gene for pentose phosphate and glyoxylate pathway modules, yaeR, rpiA, rpiB, purH, pyrB, pyrI, cysQ, pyrC, gmk, guaA, guaB, ndk, pyrF, pyrE, pyrH or hpt;

(c) a gene for TCA cycle and oxidative phosphorylation modules, frdD, frdA, sdhA, sdhB, sdhC, sdhD, sucC, sucD, cyoA or cyoB;

(d) a gene for carbohydrate metabolism module, aceF, pgi, lpdA, ppk, ptsH, ptsI, glcF, glcE, fsaA or agaW;

(e) a gene for 6-dEB precursor metabolism module, yjiM, scpA, scpB, tdcD, tdcE, pflB, pflD, PaaF, ackA, pta or ybiW;

(f) a gene target for fatty acid metabolism module, fadJ, fadB, dhaK1, dhaK2 or dhaH;

(g) a gene for amino acid and protein synthetic metabolism modules, leuC, leuD, serC, serB, serA, gdhA or tnaA; or

(h) the combination of frdD+sucC, the combination of lsrC+frdD, the combination of lsrC+sucC, the combination of frdD+rpiA, the combination of talA+guaB or the combination of zwf+guaB; and

(2) culturing the strain prepared in step (1), thereby synthesizing the polyketide 6-deoxyerythronolide biologically.

In a preferred embodiment, attenuating the expression of a target gene in the host strain for synthesizing the polyketide 6-deoxyerythronolide includes: introducing an interfering molecule that inhibits the expression of the target gene or knocking out the target gene.

In another preferred embodiment, the interfering molecule that inhibits the expression of the target gene is directed to the following (or has the same itself):

a sequence shown in SEQ ID NO: 37 in sucC or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 2 in tdcD or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 3 in scpB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 4 in scpA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 5 in ybiW or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 6 in pflB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 7 in tdcE or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 8 in pflD or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 9 in paaF or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 10 in fadJ or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 11 in fadB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 12 in ackA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 13 in pta or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 14 in leuD or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 15 in leuC or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 16 in yjiM or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 17 in purT or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 18 in dhaK1 or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 19 in dhaK2 or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 20 in dhaH or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 21 in ptsH or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 22 in ptsI or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 23 in fsaA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 24 in ppk or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 25 in aceF or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 26 in cyoA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 30 in frdD or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 31 in frdA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 32 in pgi or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 33 in sdhA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 34 in sdhB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 35 in sdhC or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 36 in sdhD or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 38 in sucD or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 39 in tnaA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 40 in glcF or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 41 in glcE or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 42 in yaeR or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 43 in lsrC or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 44 in hemN or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 45 in agaW or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 46 in gdhA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 47 in cyoB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 48 in rpiA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 49 in rpiB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 50 in lpdA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 51 in serC or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 28 in serB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 29 in serA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 174 in zwf or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 175 in pgl or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 176 in gnd or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 177 in rpe or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 178 in talA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 179 in talB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 180 in tktA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 181 in tktB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 182 in ulaE or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 183 in yieK or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 184 in purH or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 185 in pyrB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 186 in pyrI or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 187 in cysQ or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 188 in pyrC or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 189 in gmk or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 190 in guaA or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 191 in guaB or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 192 in ndk or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 193 in pyrF or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 194 in pyre or a complementary sequence thereof,

a sequence shown in SEQ ID NO: 195 in pyrH or a complementary sequence thereof, or

a sequence shown in SEQ ID NO: 196 in hpt or a complementary sequence thereof.

In another preferred embodiment, in (1) of the method, the target gene is selected from:

(a) a gene for nucleotide synthesis and other metabolism modules, lsrC, zwf, pgl, gnd, rpe, talA, talB, tktA, tktB, ulaE or yieK;

(b) a gene for pentose phosphate and glyoxylate pathway modules, rpiA, purH, pyrB, pyrI, cysQ, pyrC, gmk, guaA, guaB, ndk, pyrF, pyrE, pyrH or hpt;

(d) a gene for carbohydrate metabolism module, ptsH, ptsI or glcE;

(e) a gene for 6-dEB precursor metabolism module, yjiM, ackA, pta or ybiW;

(f) a gene target for fatty acid metabolism module, fadB or dhaK2;

(g) a gene for amino acid and protein synthetic metabolism modules, serC; or

(h) the combination of frdD+sucC, the combination of lsrC+frdD, the combination of lsrC+sucC, the combination of talA+guaB or the combination of zwf+guaB.

In another preferred embodiment, the interfering molecule that inhibits the expression of the target gene is sRNA.

In another preferred embodiment, the sRNA comprises the following structure:

a promoter, a target gene-inhibiting molecule (e.g., a target gene-binding sequence) and a terminator.

In another preferred embodiment, the promoter is selected from: Pr promoter (preferably, having the sequence of position 7 to position 61 in SEQ ID NO: 52), P_BADpromoter, T7 promoter and Trc promoter.

In another preferred embodiment, the terminator is selected from: TE terminator (preferably, having the sequence of position 171 to position 310 in SEQ ID NO: 52), T1/TE terminator, T7 terminator, rrnB terminator, rrnB T1 and T2 terminators.

In another preferred embodiment, the following is also included between the interfering molecule that inhibits the expression of the target gene and the terminator: micF sequence (e.g., the sequence of position 110 to position 170 in SEQ ID NO: 52).

In another preferred embodiment, the target gene-inhibiting molecule is a short nucleic acid sequence, such as 18-26 bp in length; and preferably 20-24 bp; which can be complementary or bind to the mRNA of the target gene, or which has a stretch of the sequence of the mRNA of the target gene, wherein the stretch of the sequence can express a sequence that is complementary or binds to the mRNA of the target gene after being transferred into a cell.

In another preferred embodiment, the sRNA is included in an expression vector.

In another preferred embodiment, the host strain for synthesizing the polyketide 6-deoxyerythronolide is a prokaryotic bacterium capable of synthesizing the polyketide 6-deoxyerythronolide.

In another preferred embodiment, the prokaryotic bacterium capable of synthesizing the polyketide 6-deoxyerythronolide is E. coli capable of synthesizing the polyketide 6-deoxyerythronolide;

preferably, in the E. coli, the operon for propionic acid metabolism is knocked out and phosphopantetheinyl transferase gene sfp is integrated into the knockout site; or the operon for propionic acid metabolism is directly knocked out and sfp is integrated into any non-essential gene or a non-functional DNA sequence region in the genome of E. coli.

In another preferred embodiment, the E. coli is transformed with a gene encoding polyketide synthetase DEBS2 of Streptomyces erythreus, a gene encoding polyketide synthetase DEBS3 of Streptomyces erythreus, a gene encoding propionyl-CoA carboxylase β-CT subunit, a gene encoding propionyl-CoA carboxylase a-CT subunit and a gene encoding polyketide synthetase DEBS1 of Streptomyces erythreus.

In another aspect of the present invention, provided is an interfering molecule that inhibits the expression of a target gene, which is an sRNA comprising the following structure (preferably, the following is also included between the interfering molecule that inhibits the expression of the target gene and the terminator: micF sequence):

a promoter, a target gene-inhibiting molecule and a terminator.

In another aspect of the present invention, provided is use of the interfering molecule (e.g., sRNA) that inhibits the expression of a target gene, for transforming a host strain for synthesizing the polyketide 6-deoxyerythronolide, attenuating the corresponding target gene or promoting a host strain for synthesizing the polyketide 6-deoxyerythronolide to synthesize the polyketide 6-deoxyerythronolide biologically

In another aspect of the present invention, provided is a host strain for synthesizing the polyketide 6-deoxyerythronolide, wherein the host strain is transformed with an interfering molecule that inhibits the expression of a target gene, or the host strain has the target gene knocked out; wherein, the target gene is selected from: (a) a gene for nucleotide synthesis and other metabolism modules, purT, lsrC, hemN, zwf, pgl, gnd, rpe, talA, talB, tktA, tktB, ulaE or yieK;

(b) a gene for pentose phosphate and glyoxylate pathway modules, yaeR, rpiA, rpiB, purH, pyrB, pyrI, cysQ, pyrC, gmk, guaA, guaB, ndk, pyrF, pyrE, pyrH or hpt;

(c) a gene for TCA cycle and oxidative phosphorylation modules, frdD, frdA, sdhA, sdhB, sdhC, sdhD, sucC, sucD, cyoA or cyoB;

(d) a gene for carbohydrate metabolism module, aceF, pgi, lpdA, ppk, ptsH, ptsI, glcF, glcE, fsaA or agaW;

(e) a gene for 6-dEB precursor metabolism module, yjiM, scpA, scpB, tdcD, tdcE, pflB, pflD, PaaF, ackA, pta or ybiW;

(f) a gene target for fatty acid metabolism module, fadJ, fadB, dhaK1, dhaK2 or dhaH;

(g) a gene for amino acid and protein synthetic metabolism modules, leuC, leuD, serC, serB, serA, gdhA or tnaA; or

(h) the combination of frdD+sucC, the combination of lsrC+frdD, the combination of lsrC+sucC, the combination of frdD+rpiA, the combination of talA+guaB or the combination of zwf+guaB.

In another preferred embodiment, the host strain is transformed with the interfering molecule (e.g., sRNA) that inhibits the expression of the target gene; and/or the host strain for synthesizing the polyketide 6-deoxyerythronolide is a prokaryotic bacterium capable of synthesizing the polyketide 6-deoxyerythronolide; preferably, in the E. coli, the operon for propionic acid metabolism is knocked out and phosphopantetheinyl transferase gene sfp is integrated into the knockout site; and preferably, the E. coli is transformed with a gene encoding polyketide synthetase DEBS2 of Streptomyces erythreus, a gene encoding polyketide synthetase DEBS3 of Streptomyces erythreus, a gene encoding propionyl-CoA carboxylase β-CT subunit, a gene encoding propionyl-CoA carboxylase a-CT subunit and a gene encoding polyketide synthetase DEBS1 of Streptomyces erythreus.

In another aspect of the present invention, provided is a kit for promoting a host strain for synthesizing the polyketide 6-deoxyerythronolide to synthesize the polyketide 6-deoxyerythronolide biologically, the kit comprising: the sum of the host strains (from which one or more strains those skilled in the art can select for production); or

the kit comprising: the sum of the interfering molecules that inhibit the expression of a target gene (from which one or more interfering molecules that inhibit the expression of the target gene those skilled in the art can select for application); or

the kit comprising: the sum of vectors that respectively comprise the interfering molecule that inhibits the expression of a target gene (from which one or more vectors those skilled in the art can select for application).

Other aspects of the present invention will be apparent to those skilled in the art from the disclosure herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1, a schematic diagram of sRNA-expressing plasmid PJF650.

FIG. 2, a schematic diagram of the construction process of E. coli WG.

FIG. 3, the construction process of plasmid pZG07.

FIG. 4, the construction process of plasmid pZG08.

FIG. 5, HPLC analysis of isolated fractions of 6-dEB.

FIG. 6, hydrogen NMR spectrum of pure 6-dEB prepared.

FIG. 7, HPLC-ELSD analysis diagram of 6-dEB at 40 mg/L.

FIG. 8, effect of sRNA combinatorial regulation on the heterologous synthesis of 6-dEB by E. coli.

DETAILED DESCRIPTION OF EMBODIMENTS

After an in-depth research, the present inventors have first disclosed a method for promoting a host strain for synthesizing the polyketide 6-dEB to synthesize the polyketide 6-dEB biologically, by attenuating individually or in combination the expression of sucC (which expresses succinyl-CoA synthetase) and other genes in E. coli, to significantly increase the yield of the polyketide heterologously synthesized in E. coli, wherein the highest yield increase rate can reach 60% or more. The present method enables massive accumulation of the polyketide in the fermentation process.

As used herein, the “interfering molecule that inhibits the expression of a target gene” refers to an agent that can specifically reduce the expression level of the target gene, including a variety of molecules known in the art that can inhibit the expression of the target gene, such as, but not limited to, antisense nucleic acids, locked nucleic acids, peptide nucleic acids, siRNAs, shRNAs and microRNAs (collectively referred to as target gene-inhibiting molecules); or constructs that carry or express antisense nucleic acids, locked nucleic acids, peptide nucleic acids, siRNAs, shRNAs, microRNAs, etc.

As used herein, the “heterologous” refers to the relationship between two or more nucleic acids or protein sequences from different sources, or the relationship between a protein (or nucleic acid) and a host cell from different sources. For example, if the combination of a nucleic acid and a host cell is usually not naturally occurring, the nucleic acid is heterologous to the host cell. A particular sequence is “heterologous” to the cell or organism into which it is inserted.

As used herein, the “host strain for synthesizing the polyketide 6-dEB” refers to a host strain or host cell known in the art that can be applied to synthesize the polyketide 6-dEB. The host strain includes, but is not limited to, E. coli and improved E. coli (including strains transformed with pccB and pccA, strains transformed with eryAI, AII and/or AIII, etc.). Preferred host strain is E. coli which has its operon for propionic acid metabolism knocked out and phosphopantetheinyl transferase gene sfp integrated into the knockout site, and which is transformed with a gene encoding polyketide synthetase DEBS2 of Streptomyces erythreus, a gene encoding polyketide synthetase DEBS3 of Streptomyces erythreus, a gene encoding propionyl-CoA carboxylase β-CT subunit, a gene encoding propionyl-CoA carboxylase a-CT subunit and a gene encoding polyketide synthetase DEBS1 of Streptomyces erythreus.

In order to optimize the formation of the polyketide 6-dEB, the present inventors have made extensive studies to find a suitable target gene for improvement, down-regulation of the expression of which helps to promote the formation of 6-dEB. The various target genes disclosed in the present invention are genes known in the art, those skilled in the art can query the sequence information of these genes through GenBank and other platforms, and it is thus easy for those skilled in the art to obtain these genes.

The present invention also provides a set of genes, wherein the set of genes comprises: (a) a gene for nucleotide synthesis and other metabolism modules, purT, lsrC, hemN, zwf, pgl, gnd, rpe, talA, talB, tktA, tktB, ulaE or yieK; (b) a gene for pentose phosphate and glyoxylate pathway modules, yaeR, rpiA, rpiB, purH, pyrB, pyrI, cysQ, pyrC, gmk, guaA, guaB, ndk, pyrF, pyrE, pyrH or hpt; (c) a gene for TCA cycle and oxidative phosphorylation modules, frdD, frdA, sdhA, sdhB, sdhC, sdhD, sucC, sucD, cyoA or cyoB; (d) a gene for carbohydrate metabolism module, aceF, pgi, lpdA, ppk, ptsH, ptsI, glcF, glcE, fsaA or agaW; (e) a gene for 6-dEB precursor metabolism module, yjiM, scpA, scpB, tdcD, tdcE, pflB, pflD, PaaF, ackA, pta or ybiW; (f) a gene target for fatty acid metabolism module, fadJ, fadB, dhaK1, dhaK2 or dhaH; and (g) a gene for amino acid and protein synthetic metabolism modules, leuC, leuD, serC, serB, serA, gdhA or tnaA. Those skilled in the art, according to the present disclosure, may select one or more genes from the set of genes to carry out the operation of the method as described in the present invention and design a material for down-regulating its expression in a host cell on the basis of the selected target gene, thereby promoting the formation of 6-dEB.

As a preferred embodiment of the present invention, the interfering molecule that inhibits the interference of a target gene is sRNA or a construct (including expression vector) carrying the sRNA. Preferably, the sRNA comprises the following structure: a promoter, a target gene-inhibiting molecule (e.g., a target gene-binding sequence) and a terminator; and preferably, the following is also included between the target gene-inhibiting molecule and the terminator: micF sequence.

The design of the promoter and terminator may be carried out according to the experience of those skilled in the art, and any suitable promoter and terminator are encompassed within the scope of the present invention. As a preferred embodiment of the present invention, the promoter is Pr promoter, and the terminator is TE terminator. However, those skilled in the art may consider changing the promoter and terminator, which are still encompassed within the scope of the present invention.

Typically, the sRNA is located in an expression vector. Accordingly, the present invention also encompasses a vector comprising the sRNA. Generally, the expression vector also contains a replication origin and/or a marker gene, etc. Methods well known to those skilled in the art can be used to construct an expression vector required for the present invention. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. It will be appreciated that any expression vector may be selected as long as the sRNA can be inserted and the expression of the target gene can be down-regulated after transforming a cell. In addition, the expression vector preferably comprises one or more selectable marker genes to provide a phenotypic trait for selecting a transformed host cell. Transformation of a host cell with an expression vector can be carried out using conventional techniques well known to those skilled in the art.

The present invention also provides a host strain for synthesizing the polyketide 6-dEB, wherein the host strain is transformed with an interfering molecule that inhibits the expression of a target gene. The host strain can efficiently produce the polyketide 6-dEB.

The present invention also provides a kit for promoting a host strain for synthesizing the polyketide 6-dEB to synthesize the polyketide 6-dEB biologically, the kit comprising: transformed with the sum of all the host strains for synthesizing the polyketide 6-dEB of the present invention (from which one or more strains those skilled in the art can select for production); and preferably, the kit comprising: transformed with the sum of the more preferred host strains for synthesizing the polyketide 6-dEB (host strains transformed with an interfering molecule that down-regulates the gene expression of the target gene or the target gene combination) of the present invention.

Or, the kit comprises: the sum of the sRNAs of the present invention (from which one or more sRNAs those skilled in the art can select for application); and preferably, the kit comprises: the sum of the more preferred sRNAs (sRNAs that down-regulate the gene expression of the target gene or the target gene combination) of the present invention.

The kit comprises: the sum of vectors that comprise the sRNA of the present invention (from which one or more vectors those skilled in the art can select for application); and preferably, the kit comprises: the sum of vectors that comprise the more preferred sRNAs (sRNAs that down-regulate the gene expression of the target gene or the target gene combination) of the present invention.

The present invention will be further illustrated with reference to specific examples below. It is to be understood that these examples are merely illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental methods not specified for the specific conditions in the following examples are generally carried out in accordance with conventional conditions, such as the conditions described in J. Sambrook et al. (eds), Molecular Cloning: A Laboratory Manual, 3rd Edition, Science Press, 2002, or in accordance with the conditions recommended by the manufacturer.

The strains, culture media and related reagents used in the present invention were as follows.

The strain E. coli DH10B was used as the clone host, and the strain E. coli WG (pZG07/pZG08) was used as the host for synthesizing the polyketide 6-dEB (see, L U Zhiguo, Doctoral Dissertation of East China University of Science and Technology, 2011). The molecular cloning-related enzymes and kits for the extraction and purification of DNA fragments and plasmids were provided by NEB, TaKaRa and Axygen, respectively. The various medium components, antibiotics and other related reagents were purchased from Oxiod, Sinopharm Group and Shanghai Bioengineering Co., Ltd. The primers were synthesized by GenScript (Nanjing) Co., Ltd.

The formulation of the 6-dEB fermentation medium involved in the present invention was as follows (g/L): NaCl, 10; peptone, 10; yeast extract, 5; glycerin, 15; and 100 mM HEPES, with pH adjusted to 7.6. The inducers involved in the present invention were as follows: IPTG: 24 μg/ml; and precursor: sodium propionate 20 mM. The induction conditions involved in the present invention were as follows: 10 ml of culture medium charged in a 100 ml shake flask was fermented and cultured for 5 days at 22° C., 250 rpm.

The antibiotic concentrations involved in the present invention were ampicillin 100 mg/L, kanamycin 50 mg/L and chloramphenicol 34 mg/L, respectively.

Example 1
Construction of sRNA-Expressing Plasmids

The present invention regulated the expression of a target gene via sRNA interference technology, that is, an sRNA was expressed to bind to the mRNA of the target gene, thereby inhibiting the binding of the mRNA of the target gene to the ribosome and then inhibiting the expression of the target gene. In the present invention, a target gene conducive to improving the synthesis of a polyketide was identified by attenuating the selected gene target.

A deoB-sRNA gene sequence fragment synthesized chemically (synthesize by Shanghai Jieduan Bioengineering Co., Ltd.) comprised Pr promoter, deoB target gene-binding site (the DNA sequence is 24 bp in length, caccataataaatgcacgtttcat (SEQ ID NO: 1); completely complementary to 24 bp starting from the ATG initiating sequence of the pentose phosphate mutase deoB gene, Genbank No. of the deoB gene: NC_012971.2), micF sequence (Genbank No.: NC_000913.3) and TE terminator, and digestion sites NdeI and HindIII were introduced at both ends. The DNA sequence of this sRNA gene sequence fragment was as follows (SEQ ID NO: 52):

catatgggatcctaacaccgtgcgtgttgactattttacctctggcggtgataatggttgccaccataataaatgc acgtttcattttctgttgggccattgcattgccactgattttccaacatataaaaagacaagcccgaacagtcgtccgggctt tttttctcgagctcgagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgtttttgtc ggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttataactagtagatctaagctt

In the construction of an sRNA-expressing plasmid, the pACYCDuet-1 plasmid (purchased from Novagen) was used as the PCR template, a vector fragment only containing chloramphenicol resistance and p15A replicon was obtained by cloning with primers pACYC-F and pACYC-R (digestion sites NdeI and HindIII were introduced at both ends of the primers), and this vector fragment was double digested with NdeI and HindIII after recovering with a cleaning and recovering kit (purchased from Axygen); and the above deoB-sRNA sequence fragment synthesized chemically was double digested with NdeI and HindIII at the same time. The double-digested vector fragment and deoB-sRNA fragment were directly recovered with the cleaning and recovering kit, and the two recovered fragments were then ligated with T4 ligase to obtain template plasmid pJF650 (FIG. 1), for attenuating the expression of the deoB gene in E. coli.

Using template plasmid pJF650 as the template together with the primers in Table 1 and the PCR conditions in Table 2, sRNA plasmid libraries were directly obtained by site-directed mutagenesis PCR amplification that were capable of attenuating the expression of different target genes as follows in E. coli: (1) genes for TCA cycle and oxidative phosphorylation modules, frdD, frdA, sdhA, sdhB, sdhC, sdhD, sucC, sucD, cyoA and cyoB; (2) genes for carbohydrate metabolism module, aceF, pgi, lpdA, ppk, ptsH, ptsI, glcF, glcE, fsaA and agaW; (3) genes for 6-dEB precursor metabolism module, yjiM, scpA, scpB, tdcD, tdcE, pflB, pflD, PaaF, ackA, pta and ybiW; (4) genes for pentose phosphate and glyoxylate pathway modules, yaeR, rpiA, rpiB, purH, pyrB, pyrI, cysQ, pyrC, gmk, guaA, guaB, ndk, pyrF, pyrE, pyrH and hpt; (5) gene targets for fatty acid metabolism module, fadJ, fadB, dhaK1, dhaK2 and dhaH; (6) genes for amino acid and protein synthetic metabolism modules, leuC, leuD, serC, serB, serA, gdhA and tnaA; and (7) genes for nucleotide synthesis and other metabolism modules, purT, lsrC, hemN, zwf, pgl, gnd, rpe, talA, talB, tktA, tktB, ulaE and yieK; wherein the sRNA plasmid libraries were pSJ01 (target gene tdcD), pSJ02 (target gene scpB), pSJ03 (target gene scpA), pSJ04 (target gene ybiW), pSJ05 (target gene pflB), pSJ06 (target gene tdcE), pSJ07 (target gene pflD), pSJ08 (target gene paaF), pSJ09 (target gene fadJ), pSJ10 (target gene fadB), pSJ11 (target gene ackA), pSJ12 (target gene pta), pSJ13 (target gene leuD), pSJ14 (target gene leuC), pSJ15 (target gene yjiM), pSJ16 (target gene purT), pSJ17 (target gene dhaK1), pSJ18 (target gene dhaK2), pSJ19 (target gene dhaH), pSJ20 (target gene ptsH), pSJ21 (target gene ptsI), pSJ22 (target gene fsaA), pSJ24 (target gene ppk), pSJ26 (target gene aceF), pSJ29 (target gene cyoA), pSJ30 (target gene frdD), pSJ33 (target gene frdA), pSJ34 (target gene pgi), pSJ35 (target gene sdhA), pSJ36 (target gene sdhB), pSJ37 (target gene sdhC), pSJ38 (target gene sdhD), pSJ39 (target gene sucC), pSJ40 (target gene sucD), pSJ41 (target gene tnaA), pSJ43 (target gene glcF), pSJ44 (target gene gleE), pSJ50 (target gene yaeR), pSJ53 (target gene lsrC), pSJ54 (target gene hemN), pSJ66 (target gene agaW), pJF663 (target gene zwf), pJF666 (target gene pgl), pJF670 (target gene gnd), pSJ128 (target gene rpe), pSJ129 (target gene talA), pSJ130 (target gene talB), pSJ131 (target gene tktA), pSJ132 (target gene tktB), pSJ133 (target gene ulaE), pSJ141 (target gene yieK), pSJ147 (target gene purH), pSJ148 (target gene pyrB), pSJ149 (target gene pyrI), pSJ150 (target gene cysQ), pSJ151 (target gene pyrC), pSJ152 (target gene gmk), pSJ153 (target gene guaA), pSJ154 (target gene guaB), pSJ155 (target gene ndk), pSJ156 (target gene pyrF), pSJ157 (target gene pyrE), pSJ158 (target gene pyrH), pSJ159 (target gene hpt), pJF656 (target gene gdhA), pJF664 (target gene cyoB), pJF667 (target gene rpiA), pJF668 (target gene rpiB), pJF671 (target gene lpdA), pJF672 (target gene serC), pJF673 (target gene serB) and pJF674 (target gene serA) (Table 3). Taking the construction of an sRNA plasmid for attenuating the target gene sucC (which expresses succinyl-CoA synthetase) as an example, the deoB target gene-binding site with a length of 24 bp in the skeleton of the pJF650 plasmid was directly mutated into sucC target gene-binding site (completely complementary to the DNA sequence with a length of 24 bp starting from the ATG initiating sequence of the sucC gene) by site-directed mutagenesis PCR using template plasmid pJF650 as the template together with the sucC-sRNA-F and sucC-sRNA-R primers in Table 1 and the PCR conditions in Table 2, obtaining sRNA plasmid pSJ39 that is capable of attenuating the expression of the sucC gene.

TABLE 1

Primers for plasmid construction

Con-

Primer
Target

structed

SEQ
gene-binding

plasmid
Primer
Primer sequence
ID
sequence

name
name
(from 5′ to 3′)
NO:
(SEQ ID NO:)

pJF650
pACYC-
CCCAAGCTTCTGAAACCTCAGGCATTTG
53

F
A

pACYC-
CGGGATCCGCGCAACGCAATTAATGTA
54

R
A

pSJ01
scpB-sRN
aacgttaacatactgataagacatTTTCTGTTGGGCCA
55
targeting scpB

A-F
TTGCATTGCC

Aacgttaacatactgata

scpB-sRN
atgtcttatcagtatgttaacgttGCAACCATTATCACC
56
agacat (2)

A-R
GCCAGAGGTA

pSJ02
tdcD-sRN
caaaacaaccggaaattcattcatTTTCTGTTGGGCCA
57
targeting tdcD

A-F
TTGCATTGCC

Caaaacaaccggaaatt

tdcD-sRN
atgaatgaatttccggttgttttgGCAACCATTATCAC
58
cattcat (3)

A-R
CGCCAGAGGTA

pSJ03
scpA-sR
ttgccactcctgcacgttagacatTTTCTGTTGGGCCA
59
targeting scpA:

NA-F
TTGCATTGCC

Ttgccactcctgcacgtt

scpA-sR
atgtctaacgtgcaggagtggcaaGCAACCATTATCA
60
agacat (4)

NA-R
CCGCCAGAGGTA

pSJ04
ybiW-sR
cgtgtccagtttcagtgtggtcatTTTCTGTTGGGCCA
61
targeting ybiW:

NA-F
TTGCATTGCC

Cgtgtccagtttcagtgt

ybiW-sR
atgaccacactgaaactggacacgGCAACCATTATC
62
ggtcat (5)

NA-R
ACCGCCAGAGGTA

pSJ05
pflB-sRN
taacttttcattaagctcggacatTTTCTGTTGGGCCAT
63
targeting pflB:

A-F
TGCATTGCC

Taacttttcattaagctcg

pflB-sRN
atgtccgagcttaatgaaaagttaGCAACCATTATCA
64
gacat (6)

A-R
CCGCCAGAGGTA

pSJ06
tdcE-sRN
gctggtatcaatatctaccttcatTTTCTGTTGGGCCAT
65
targeting tdcE:

A-F
TGCATTGCC

Gctggtatcaatatctac

tdcE-sRN
atgaaggtagatattgataccagcGCAACCATTATCA
66
cttcat (7)

A-R
CCGCCAGAGGTA

pSJ07
pflD-sRN
gaggcgagagatacgattcgtcatTTTCTGTTGGGCC
67
targeting pflD:

A-F
ATTGCATTGCC

Gaggcgagagatacga

pflD-sRN
atgacgaatcgtatctctcgcctcGCAACCATTATCAC
68
ttcgtcat (8)

A-R
CGCCAGAGGTA

pSJ08
paaF-sRN
acggctgacgatcagttcgctcatTTTCTGTTGGGCC
69
targeting paaF:

A-F
ATTGCATTGCC

Acggctgacgatcagtt

paaF-sRN
atgagcgaactgatcgtcagccgtGCAACCATTATCA
70
cgctcat (9)

A-R
CCGCCAGAGGTA

pSJ09
fadJ-sRN
ggtaaacgctgatgtcatttccatTTTCTGTTGGGCCA
71
targeting fadJ:

A-F
TTGCATTGCC

Ggtaaacgctgatgtcat

fadJ-sRN
atggaaatgacatcagcgtttaccGCAACCATTATCA
72
ttccat (10)

A-R
CCGCCAGAGGTA

pSJ10
fadB-sRN
cagggtgtcgcctttgtaaagcatTTTCTGTTGGGCCA
73
targeting fadB:

A-F
TTGCATTGCC

Cagggtgtcgcctttgta

fadB-sRN
atgctttacaaaggcgacaccctgGCAACCATTATCA
74
aagcat (11)

A-R
CCGCCAGAGGTA

pSJ11
ackA-sR
aaccagtactaacttactcgacatTTTCTGTTGGGCCA
75
targeting ackA:

NA-F
TTGCATTGCC

Aaccagtactaacttact

ackA-sR
atgtcgagtaagttagtactggttGCAACCATTATCAC
76
cgacat (12)

NA-R
CGCCAGAGGTA

pSJ12
pta-sRNA-
gatcagcataataatacgggacacTTTCTGTTGGGCC
77
targeting pta:

F
ATTGCATTGCC

Gatcagcataataatacg

pta-sRNA-
gtgtcccgtattattatgctgatcGCAACCATTATCAC
78
ggacac (13)

R
CGCCAGAGGTA

pSJ13
leuD-sRN
gtgtttgataaatttctctgccatTTTCTGTTGGGCCAT
79
targeting leuD:

A-F
TGCATTGCC

Gtgtttgataaatttctctg

leuD-sRN
atggcagagaaatttatcaaacacGCAACCATTATCA
80
ccat (14)

A-R
CCGCCAGAGGTA

pSJ14
leuC-sRN
tttttcgtataacgtcttagccatTTTCTGTTGGGCCAT
81
targeting leuC:

A-F
TGCATTGCC

Tttttcgtataacgtcttag

leuC-sRN
atggctaagacgttatacgaaaaaGCAACCATTATCA
82
ccat (15)

A-R
CCGCCAGAGGTA

pSJ15
yjiM-sRN
gggtagatcggtgacaagtgacatTTTCTGTTGGGCC
83
targeting yjiM:

A-F
ATTGCATTGCC

Gggtagatcggtgacaa

yjiM-sRN
atgtcacttgtcaccgatctacccGCAACCATTATCAC
84
gtgacat (16)

A-R
CGCCAGAGGTA

pSJ16
purT-sRN
cagcgcagtgcctaataacgtcatTTTCTGTTGGGCC
85
targeting purT:

A-F
ATTGCATTGCC

Cagcgcagtgcctaata

purT-sRN
atgacgttattaggcactgcgctgGCAACCATTATCA
86
acgtcat (17)

A-R
CCGCCAGAGGTA

pSJ17
dhaK1-sR
cacatcattgatcaattttttcatTTTCTGTTGGGCCAT
87
targeting dhaK1:

NA-F
TGCATTGCC

Cacatcattgatcaattttt

dhaK1-sR
atgaaaaaattgatcaatgatgtgGCAACCATTATCA
88
tcat (18)

NA-R
CCGCCAGAGGTA

pSJ18
dhaK2-sR
aatttgagttctgctcagtgacatTTTCTGTTGGGCCA
89
targeting dhaK2

NA-F
TTGCATTGCC

Aatttgagttctgctcagt

dhaK2-sR
atgtcactgagcagaactcaaattGCAACCATTATCA
90
gacat (19)

NA-R
CCGCCAGAGGTA

pSJ19
dhaH-sR
tgaaactatgaccaggtttaccatTTTCTGTTGGGCCA
91
targeting dhaH:

NA-F
TTGCATTGCC

Tgaaactatgaccaggtt

dhaH-sR
atggtaaacctggtcatagtttcaGCAACCATTATCAC
92
taccat (20)

NA-R
CGCCAGAGGTA

pSJ20
ptsH-sRN
aatggtaacttcttgctggaacatTTTCTGTTGGGCCA
93
targeting ptsH:

A-F
TTGCATTGCC

Aatggtaacttcttgctg

ptsH-sRN
atgttccagcaagaagttaccattGCAACCATTATCAC
94
gaacat (21)

A-R
CGCCAGAGGTA

pSJ21
ptsI-sRN
ggatgctaaaatgcctgaaatcatTTTCTGTTGGGCCA
95
targeting ptsI:

A-F
TTGCATTGCC

Ggatgctaaaatgcctg

ptsI-sRN
atgatttcaggcattttagcatccGCAACCATTATCAC
96
aaatcat (22)

A-R
CGCCAGAGGTA

pSJ22
fsaA-sRN
tgaagtatccagatacagttccatTTTCTGTTGGGCCA
97
targeting fsaA:

A-F
TTGCATTGCC

Tgaagtatccagataca

fsaA-sRN
atggaactgtatctggatacttcaGCAACCATTATCAC
98
gttccat (23)

A-R
CGCCAGAGGTA

pSJ24
ppk-sRN
gatgtatagcttttcctgacccatTTTCTGTTGGGCCA
99
targeting ppk:

A-F
TTGCATTGCC

Gatgtatagcttttcctga

ppk-sRN
atgggtcaggaaaagctatacatcGCAACCATTATCA
100
cccat (24)

A-R
CCGCCAGAGGTA

pSJ26
aceF-sRN
cggtactttgatttcgatagccatTTTCTGTTGGGCCA
101
targeting aceF:

A-F
TTGCATTGCC

Cggtactttgatttcgata

aceF-sRN
atggctatcgaaatcaaagtaccgGCAACCATTATCA
102
gccat (25)

A-R
CCGCCAGAGGTA

pSJ29
cyoA-sR
tttattgtatttcctgagtctcatTTTCTGTTGGGCCATT
103
targeting cyoA:

NA-F
GCATTGCC

Tttattgtatttcctgagtc

cyoA-sR
atgagactcaggaaatacaataaaGCAACCATTATCA
104
tcat (26)

NA-R
CCGCCAGAGGTA

pSJ30
frdD-sRN
acgctttggatttggattaatcatTTTCTGTTGGGCCAT
105
targeting frdD:

A-F
TGCATTGCC

Acgctttggatttggatta

frdD-sRN
atgattaatccaaatccaaagcgtGCAACCATTATCA
106
atcat (30)

A-R
CCGCCAGAGGTA

pSJ33
frdA-sRN
aagatcggcttgaaaggtttgcacTTTCTGTTGGGCC
107
targeting frdA:

A-F
ATTGCATTGCC

Aagatcggcttgaaagg

frdA-sRN
gtgcaaacctttcaagccgatcttGCAACCATTATCAC
108
tttgcac (31)

A-R
CGCCAGAGGTA

pSJ34
pgi-sRNA-
ctgcgttggattgatgtttttcatTTTCTGTTGGGCCAT
109
targeting pgi:

F
TGCATTGCC

Ctgcgttggattgatgtttt

pgi-sRNA-
atgaaaaacatcaatccaacgcagGCAACCATTATCA
110
tcat (32)

R
CCGCCAGAGGTA

pSJ35
sdhA-sR
aaattctctgactggcaatttcatTTTCTGTTGGGCCAT
111
targeting sdhA:

NA-F
TGCATTGCC

Aaattctctgactggcaa

sdhA-sR
atgaaattgccagtcagagaatttGCAACCATTATCA
112
tttcat (33)

NA-R
CCGCCAGAGGTA

pSJ36
sdhB-sR
ataaattgaaaactcgagtctcatTTTCTGTTGGGCCA
113
targeting sdhB:

NA-F
TTGCATTGCC

Ataaattgaaaactcgag

sdhB-sR
atgagactcgagttttcaatttatGCAACCATTATCAC
114
tctcat (34)

NA-R
CGCCAGAGGTA

pSJ37
sdhC-sR
ttgttttttcacatttcttatcatTTTCTGTTGGGCCATT
115
targeting sdhC:

NA-F
GCATTGCC

Ttgttttttcacatttcttat

sdhC-sR
atgataagaaatgtgaaaaaacaaGCAACCATTATCA
116
cat (35)

NA-R
CCGCCAGAGGTA

pSJ38
sdhD-sR
taatgcggaggcgttgcttaccatTTTCTGTTGGGCCA
117
targeting sdhD:

NA-F
TTGCATTGCC

Taatgcggaggcgttgc

sdhD-sR
atggtaagcaacgcctccgcattaGCAACCATTATCA
118
ttaccat (36)

NA-R
CCGCCAGAGGTA

pSJ39
sucC-sRN
tgcctgatattcatgtaagttcatTTTCTGTTGGGCCAT
119
targeting sucC:

A-F
TGCATTGCC

Tgcctgatattcatgtaa

sucC-sRN
atgaacttacatgaatatcaggcaGCAACCATTATCA
120
gttcat (37)

A-R
CCGCCAGAGGTA

pSJ40
sucD-sR
gtttttatcgattaaaatggacatTTTCTGTTGGGCCAT
121
targeting sucD:

NA-F
TGCATTGCC

Gtttttatcgattaaaatg

sucD-sR
atgtccattttaatcgataaaaacGCAACCATTATCAC
122
gacat (38)

NA-R
CGCCAGAGGTA

pSJ41
tnaA-sRN
agggagatgtttaaagttttccatTTTCTGTTGGGCCA
123
targeting tnaA:

A-F
TTGCATTGCC

Agggagatgtttaaagtt

tnaA-sRN
atggaaaactttaaacatctccctGCAACCATTATCAC
124
ttccat (39)

A-R
CGCCAGAGGTA

pSJ43
glcF-sRN
ctcttcagttaattgggtttgcatTTTCTGTTGGGCCAT
125
targeting glcF:

A-F
TGCATTGCC

Ctcttcagttaattgggttt

glcF-sRN
atgcaaacccaattaactgaagagGCAACCATTATCA
126
gcat (40)

A-R
CCGCCAGAGGTA

pSJ44
glcE-sRN
gctgtaatcacactcgcgtagcatTTTCTGTTGGGCCA
127
targeting glcE:

A-F
TTGCATTGCC

Gctgtaatcacactcgcg

glcE-sRN
atgctacgcgagtgtgattacagcGCAACCATTATCA
128
tagcat (41)

A-R
CCGCCAGAGGTA

pSJ50
yaeR-sR
gtgaacctgttttaaacccagcatTTTCTGTTGGGCCA
129
targeting yaeR:

NA-F
TTGCATTGCC

Gtgaacctgttttaaacc

yaeR-sR
atgctgggtttaaaacaggttcacGCAACCATTATCA
130
cagcat (42)

NA-R
CCGCCAGAGGTA

pSJ53
lsrC-sRN
gttgttctgaataaacttcagcatTTTCTGTTGGGCCA
131
targeting lsrC:

A-F
TTGCATTGCC

Gttgttctgaataaacttc

lsrC-sRN
atgctgaagtttattcagaacaacGCAACCATTATCAC
132
agcat (43)

A-R
CGCCAGAGGTA

pSJ54
hemN-sR
ccagtcgatttgctgtacagacatTTTCTGTTGGGCCA
133
targeting hemN:

NA-F
TTGCATTGCC

Ccagtcgatttgctgtac

hemN-sR
atgtctgtacagcaaatcgactggGCAACCATTATCA
134
agacat (44)

NA-R
CCGCCAGAGGTA

pSJ66
agaW-sR
tgcctgcaacaggctgatttccatTTTCTGTTGGGCCA
135
targeting agaW:

NA-F
TTGCATTGCC

Tgcctgcaacaggctga

agaW-sR
atggaaatcagcctgttgcaggcaGCAACCATTATCA
136
tttccat (45)

NA-R
CCGCCAGAGGTA

pJF656
gdhA-F
ctccagagaatatgtctgatccatTTTCTGTTGGGCCA
137
targeting gdhA:

TTGCAT

Ctccagagaatatgtctg

gdhA-R
ATGGATCAGACATATTCTCTGGAGGCAA
138
atccat (46)

CCATTATCACCGCCAG

pJF664
cyoB-F
ATCAAGTGATAATTTTCCGAACATTTTC
140
targeting cyoB:

TGTTGGGCCATTGCAT

Atgttcggaaaattatca

cyoB-B
atgttcggaaaattatcacttgatGCAACCATTATCAC
141
cttgat (47)

CGCCAG

pJF667
rpiA-F
ttttttcaattcatcctgcgtcatTTTCTGTTGGGCCAT
142
targeting rpiA:

TGCAT

Ttttttcaattcatcctgcg

rpiA-R
ATGACGCAGGATGAATTGAAAAAAGCA
143
tcat (48)

ACCATTATCACCGCCAG

pJF668
rpiB-F
acagccaaatgcaatctttttcatTTTCTGTTGGGCCA
144
targeting rpiB:

TTGCAT

Acagccaaatgcaatctt

rpiB-R
ATGAAAAAGATTGCATTTGGCTGTGCAA
145
tttcat (49)

CCATTATCACCGCCAG

pJF671
lpdA-F
ctgagttttgatttcagtactcatTTTCTGTTGGGCCAT
146
targeting lpdA:

TGCAT

Ctgagttttgatttcagta

lpdA-R
ATGAGTACTGAAATCAAAACTCAGGCA
147
ctcat (50)

ACCATTATCACCGCCAG

pJF672
serC-F
actaaaattgaagatttgagccatTTTCTGTTGGGCCA
148
targeting serC:

TTGCAT

Actaaaattgaagatttg

serC-R
ATGGCTCAAATCTTCAATTTTAGTGCAA
149
agccat (51)

CCATTATCACCGCCAG

pJF673
serB-F
gtcgcaccaggtaatgttaggcatTTTCTGTTGGGCC
150
targeting serB:

ATTGCAT

Gtcgcaccaggtaatgtt

serB-R
ATGCCTAACATTACCTGGTGCGACGCAA
151
aggcat (28)

CCATTATCACCGCCAG

pJF674
serA-F
tttctccagcgatacctttgccatTTTCTGTTGGGCCAT
152
targeting serA:

TGCAT

Tttctccagcgataccttt

serA-R
ATGGCAAAGGTATCGCTGGAGAAAGCA
153
gccat (29)

ACCATTATCACCGCCAG

pJF663
zwf-sRN
ctgggctgtttgcgttaccgccatTTTCTGTTGGGCCA
197
targeting zwf:

A-R
TTGCAT

Ctgggctgtttgcgttac

zwf-sRN
atggcggtaacgcaaacagcccagGCAACCATTATC
198
cgccat (174)

A-R
ACCGCCAG

pJF666
pgl-sRNA-
ggcgatataaactgtttgcttcatTTTCTGTTGGGCCA
199
targeting pgl:

F
TTGCAT

Ggcgatataaactgtttg

pgl-sRNA-
ATGAAGCAAACAGTTTATATCGCCGCAA
200
cttcat (175)

F
CCATTATCACCGCCAG

pJF670
gnd-sRN
tacgccgatctgttgcttggacatTTTCTGTTGGGCCA
201
targeting gnd:

A-F
TTGCAT

tacgccgatctgttgcttg

gndsRNA-
ATGTCCAAGCAACAGATCGGCGTAGCA
202
gacat (176)

F
ACCATTATCACCGCCAG

pSJ128
rpe-sRNA-
gggggcaatcaaatactgtttcatTTTCTGTTGGGCCA
203
targeting rpe:

F
TTGCATTGCC

gggggcaatcaaatact

rpe-sRNA-
atgaaacagtatttgattgcccccGCAACCATTATCAC
204
gtttcat (177)

R
CGCCAGAGGTA

pSJ129
talA-sRN
tttgatgccgtctaactcgttcatTTTCTGTTGGGCCAT
205
targeting talA:

A-F
TGCATTGCC

tttgatgccgtctaactcgt

ta1A-sRN
atgaacgagttagacggcatcaaaGCAACCATTATCA
206
tcat (178)

A-R
CCGCCAGAGGTA

pSJ130
ta1B-sRN
aagggaggtcaatttgtccgtcatTTTCTGTTGGGCCA
207
targeting talB:

A-F
TTGCATTGCC

aagggaggtcaatttgtc

talB-sRN
atgacggacaaattgacctcccttGCAACCATTATCA
208
cgtcat (179)

A-R
CCGCCAGAGGTA

pSJ131
tktA-sRN
ggcaagctctttacgtgaggacatTTTCTGTTGGGCC
209
targeting tktA:

A-F
ATTGCATTGCC

Ggcaagctctttacgtga

tktA-sRN
atgtcctcacgtaaagagcttgccGCAACCATTATCA
210
ggacat (180)

A-R
CCGCCAGAGGTA

pSJ132
tktB-sRN
attggcaaggtcttttcgggacatTTTCTGTTGGGCCA
211
targeting tktB:

A-F
TTGCATTGCC

attggcaaggtcttttcgg

tktB-sRN
atgtcccgaaaagaccttgccaatGCAACCATTATCA
212
gacat (181)

A-R
CCGCCAGAGGTA

pSJ133
ulaE-sRN
aagcgggatttgtttggacaacatTTTCTGTTGGGCCA
213
targeting ulaE:

A-F
TTGCATTGCC

aagcgggatttgtttgga

ulaE-sRN
atgttgtccaaacaaatcccgcttGCAACCATTATCAC
214
caacat (182)

A-R
CGCCAGAGGTA

pSJ141
yieK-sRN
atcttcggtaatgattaatttcatTTTCTGTTGGGCCAT
215
targeting yieK:

A-F
TGCATTGCC

atcttcggtaatgattaatt

yieK-sRN
atgaaattaatcattaccgaagatGCAACCATTATCAC
216
tcat (183)

A-R
CGCCAGAGGTA

pSJ147
purH-sR
gcggactggacgacgttgttgcatTTTCTGTTGGGCC
217
targeting purH:

NA-F
ATTGCATTGCC

gcggactggacgacgtt

purH-sR
atgcaacaacgtcgtccagtccgcGCAACCATTATCA
218
gttgcat (184)

NA-R
CCGCCAGAGGTA

pSJ148
pyrB-sRN
tttctgatatagcggattagccatTTTCTGTTGGGCCA
219
targeting pyrB:

A-F
TTGCATTGCC

tttctgatatagcggatta

pyrB-sRN
atggctaatccgctatatcagaaaGCAACCATTATCA
220
gccat (185)

A-R
CCGCCAGAGGTA

pSJ149
pyrI-sRN
ctgcaatttattatcgtgtgtcatTTTCTGTTGGGCCAT
221
targeting pyrI:

A-F
TGCATTGCC

ctgcaatttattatcgtgtg

pyrI-sRN
atgacacacgataataaattgcagGCAACCATTATCA
222
tcat (186)

A-R
CCGCCAGAGGTA

pSJ150
cysQ-sR
aagctggcatacttgatctaacatTTTCTGTTGGGCCA
223
targeting cysQ:

NA-F
TTGCATTGCC

aagctggcatacttgatct

cysQ-sR
atgttagatcaagtatgccagcttGCAACCATTATCAC
224
aacat (187)

NA-R
CGCCAGAGGTA

pSJ151
pyrC-sRN
taatacctgggatggtgcagtcatTTTCTGTTGGGCCA
225
targeting pyrC:

A-F
TTGCATTGCC

taatacctgggatggtgc

pyrC-sRN
atgactgcaccatcccaggtattaGCAACCATTATCA
226
agtcat (188)

A-R
CCGCCAGAGGTA

pSJ152
gmk-sRN
aatataaagcgtgccttgagccatTTTCTGTTGGGCCA
227
targeting gmk:

A-F
TTGCATTGCC

aatataaagcgtgccttg

gmk-sRN
atggctcaaggcacgctttatattGCAACCATTATCAC
228
agccat (189)

A-R
CGCCAGAGGTA

pSJ153
guaA-sR
atgcttatgaatgttttccgtcatTTTCTGTTGGGCCAT
229
targeting guaA:

NA-F
TGCATTGCC

atgcttatgaatgttttccg

guaA-sR
atgacggaaaacattcataagcatGCAACCATTATCA
230
tcat (190)

NA-R
CCGCCAGAGGTA

pSJ154
guaB-sR
agcttctttagcgatacgtagcatTTTCTGTTGGGCCA
231
targeting guaB:

NA-F
TTGCATTGCC

agcttctttagcgatacgt

guaB-sR
atgctacgtatcgctaaagaagctGCAACCATTATCA
232
agcat (191)

NA-R
CCGCCAGAGGTA

pSJ155
ndk-sRN
ggaaaaagtacgttcaatagccatTTTCTGTTGGGCC
233
targeting ndk:

A-F
ATTGCATTGCC

ggaaaaagtacgttcaat

ndk-sRN
atggctattgaacgtactttttccGCAACCATTATCAC
234
agccat (192)

A-R
CGCCAGAGGTA

pSJ156
pyrF-sRN
agaagatgaagcagttaacgtcatTTTCTGTTGGGCC
235
targeting pyrF:

A-F
ATTGCATTGCC

agaagatgaagcagttaa

pyrF-sRN
atgacgttaactgcttcatcttctGCAACCATTATCAC
236
cgtcat (193)

A-R
CGCCAGAGGTA

pSJ157
pyrE-sRN
aaactggcgctgatatggtttcatTTTCTGTTGGGCCA
237
targeting pyrE:

A-F
TTGCATTGCC

aaactggcgctgatatgg

pyrE-sRN
atgaaaccatatcagcgccagtttGCAACCATTATCA
238
tttcat (194)

A-R
CCGCCAGAGGTA

pSJ158
pyrH-sR
gacgggttttgcattggtagccatTTTCTGTTGGGCCA
239
targeting pyrH:

NA-F
TTGCATTGCC

gacgggttttgcattggta

pyrH-sR
atggctaccaatgcaaaacccgtcGCAACCATTATCA
240
gccat (195)

NA-R
CCGCCAGAGGTA

pSJ159
hpt-sRNA-
cattacttctacagtatgtttcatTTTCTGTTGGGCCAT
241
targeting hpt:

F
TGCATTGCC

cattacttctacagtatgttt

hpt-sRNA-
atgaaacatactgtagaagtaatgGCAACCATTATCA
242
cat (196)

R
CCGCCAGAGGTA

TABLE 2

PCR conditions

Name
Conditions

System
2x GC buffer I: 25 μl; upstream and downstream primers:

each 1 μl; dNTP: 5 μl; template plasmid: 0.3μ; enayme LA-

Taq: 0.5 μl; ddH₂O: the reaction system was made up to 50 μl;

Program
pre-denaturation at 95° C.: 3 min; 30 cycles: denaturation

at 94° C.: 30 s, annealing at 55° C.: 30 s, and extending at

72° C.: 3 min; 72° C.: 10 min; maintaining at 16° C.

TABLE 3

Regulation of target function through sRNA technology

Target

regulated

through sRNA

Plasmid
Genbank No.
technology
Target function

pSJ39
NC_012971.2
sucC
succinyl-CoA synthetase, βsubunit

pSJ15
NC_012971.2
yjiM
hypothetical protein

pSJ30
NC_012892.2
frdD
fumarate reductase

pSJ53
NC_012892.2
lsrC
Autoinducer-2ABC transporter

pSJ44
NC_012971.2
glcE
glycolate oxidase, FAD-binding subunit

pSJ04
NC_012971.2
ybiW
pyruvate formatelyase

pSJ35
NC_012971.2
sdhA
succinate dehydrogenase

pSJ20
NC_012892.2
ptsH
HPr protein of phosphoenolpyruvate-sugar

phosphotransferase system (PTS system)

npSJ18
NC_012971.2
dhaK2
dihydroxyacetone kinase

pSJ40
NC_012971.2
sucD
succinyl-CoA synthetase

pSJ33
NC_012971.2
frdA
fumarate reductase, αsubunit

pSJ21
NC_012971.2
ptsI
PTSI protein of phosphoenolpyruvate-sugar

phosphotransferase system (PTS system)

pSJ10
NC_012971.2
fadB
fatty acid oxidation complex, α component

pSJ11
NC_012971.2
ackA
acetate kinase

pJF672
NC_012971.2
serC
3-phosphoserine/phosphohydroxythreonine

aminotransferase

pJF667
NC_012971.2
rpiA
ribose-5-phosphate isomerase A

pSJ12
NC_012971.2
pta
phosphate acetyltransferase/phosphate

propionyltransferase

pSJ05
NC_012971.2
pflB
pyruvate formatelyase (inactive)

pSJ17
NC_012971.2
dhaK1
dihydroxyacetone kinase subunit K

pJF673
NC_012971.2
serB
phosphoserine phosphatase

pSJ13
NC_012892.2
leuD
isopropylmalate isomerase

pSJ36
NC_012892.2
sdhB
succinate dehydrogenase

pSJ14
NC_012892.2
leuC
isopropylmalate isomerase LeuC

pSJ22
NC_012892.2
fsaA
fructose 6-phosphate aldolase 1

pSJ06
NC_012892.2
tdcE
2-ketobutyrate formatelyase/pyruvate

formatelyase 4, inactive

pSJ38
NC_012892.2
sdhD
succinate dehydrogenase

pSJ09
NC_012892.2
fadJ
FadJ component of anaerobic fatty acid

oxidation complex

pJF668
NC_012971.2
rpiB
allose-6-phosphate

isomerase/ribose-5-phosphate isomerase B

pSJ34
NC_012892.2
pgi
phosphoglucose isomerase

pSJ43
NC_012892.2
glcF
glycolateoxidase, predicted iron-sulfur

subunit

pSJ01
NC_012892.2
scpB
methylmalonyl-CoA decarboxylase

pSJ02
NC_012892.2
tdcD
propionate kinase

pSJ03
NC_012892.2
scpA
methylmalonyl-CoA mutase

pSJ37
NC_012892.2
sdhC
succinate dehydrogenase

pSJ19
NC_007779.1
dhaH
dihydroxyacetone kinase subunit M

pSJ24
NC_012971.2
ppk
polyphosphate kinase

pJF671
NC_012971.2
lpdA
lipoamide dehydrogenase

pSJ29
NC_012971.2
cyoA
cytochrome bo terminal oxidase subunit II

pSJ26
NC_012892.2
aceF
pyruvatede hydrogenase

pSJ08
NC_007779.1
PaaF
predicted 2,3-dehydroadipyl-CoA hydratase

pSJ16
NC_012971.2
purT
phosphoribosyl glycinamide

formyltransferase 2

pJF656
NC_012971.2
gdhA
glutamate dehydrogenase

pSJ66
NC_012971.2
agaW
N-acetylgalactosameine-specific IIC

component 2 of PTS system

pJF674
NC_012971.2
serA
D-3-phosphoglycerate

dehydrogenase/α-ketoglutarate reductase

pSJ50
NC_012971.2
yaeR
predicted lyase

pSJ41
NC_012971.2
tnaA
tryptophanase/L-cysteine desulfhydrase

pSJ07
NC_012971.2
pflD
formate acetyltransferase 2

pSJ54
NC_012971.2
hemN
coproporphyrinogen III dehydrogenase

pJF664
NC_012971.2
cyoB
cytochrome bo terminal oxidase subunit I

pJF663
NC_000913.3
zwf
glucose 6-phosphate-1-dehydrogenase

pJF666
NC_000913.3
pgl
6-phosphogluconolactonase

pJF670
NC_000913.3
gnd
6-phosphogluconate dehydrogenase

pSJ128
NC_007779.1
rpe
ribulose-5-phosphate 3-epimerase

pSJ129
NC_000913.3
talA
transaldolase A

pSJ130
NC_000913.3
talB
transaldolase

pSJ131
NC_000913.3
tktA
transketolase I

pSJ132
NC_000913.3
tktB
transketolase II

pSJ133
NC_000913.3
ulaE
L-xylulose 5-phosphate 3-epimerase

pSJ141
NC_000913.3
yieK
predicted 6-phosphogluconolactonase

pSJ147
NC_000913.3
purH
AICAR transformylase

pSJ148
NC_000913.3
pyrB
aspartate carbamoyltransferase,

catalytic subunit

pSJ149
NC_000913.3
pyrI
aspartate carbamoyltransferase,

regulatory subunit

pSJ150
NC_000913.3
cysQ
adenosine-3′(2′),5′-bisphosphate

nucleotidase

pSJ151
NC_000913.3
pyrC
dihydroorotase

pSJ152
NC_000913.3
gmk
guanylate kinase

pSJ153
NC_000913.3
guaA
GMP synthetase

pSJ154
NC_000913.3
guaB
IMP dehydrogenase

pSJ155
NC_000913.3
ndk
nucleoside diphosphate kinase

pSJ156
NC_000913.3
pyrF
orotidine-5′-phosphate decarboxylase

pSJ157
NC_000913.3
pyrE
orotate phosphoribosyltransferase

pSJ158
NC_000913.3
pyrH
UMP kinase

pSJ159
NC_000913.3
hpt
hypoxanthine phosphoribosyltransferase

Example 2
Construction of an E. coli WG Strain

The operon for propionic acid metabolism was knocked out in E. coli and phosphopantetheinyl transferase gene sfp from the gene cluster of the surfactin synthesis pathway in B. subtilis was integrated into the site to construct an E. coli WG strain suitable for the biosynthesis of a polyketide, wherein the specific steps were as follows:

first, the sfp gene (encoding phosphopantetheinyl transferase, Genbank No.: NC_000964) with a length of 675 bp was amplified by PCR using the genome of B. subtilis as the template together with primers sfp-F and sfp-R (Table 4), and then the PCR product and plasmid pET21c-sfp (purchased from Novagen) were ligated with T4 DNA ligase after being respectively digested with NdeI and BamHI, constructing plasmid pET21c-sfp;

then, a Kan-SacB fragment (about 2.8 Kb) having a selective marker gene with homologous arms was amplified using plasmid pUC19-sacB/kan as the template together with primers SacB/Kan-F and SacB/Kan-R (Table 4), and then Kan-SacB was integrated into the operon for propionic acid metabolism in the chromosome of E. coli BL21 (DE3) using the λ Red/ET homologous recombination method (Datsenki et al., PNAS, 2000, 97: 6640-6645), replacing the DNA fragments of prpR, prpB, prpC and prpD in the operon for propionic acid metabolism; using WG-F and WG-R as the primers, the SacB/Kan gene located in the chromosome of the recombinant strain was amplified for verification;

then, the T7 promoter-carrying sfp gene was amplified from pET21c-sfp using sfpR-F and sfpR-R; and the SacB-Kan fragment of the recombinant strain was replaced with the T7-sfp-T7 fragment again using the λ Red/ET homologous recombination method, and finally an E. coli WG strain required by the present invention was obtained that was suitable for the biosynthesis of a polyketide, wherein the schematic diagram of the specific restructuring process was as shown in FIG. 2.

TABLE 4

Primers used in this example and the

corresponding base sequences thereof

SEQ

ID

Primer
Base sequence
NO:

Sfp-F
CTAGGGATCCTTATAAAAGCTCTTCGTACG
154

Sfp-R
GGAATTCCATATGATGAAGATTTACGGAATTTA
155

sfpR-F
TGGCGTAATGCAGCAGAAAATGGCCCGCGAAATTAAT
156

ACGACTCACTATAGG

sfpR-R
GATAAAATTCGCTAAAAGACATATGTATATCTCCTTCT
157

TAAAGTTAAACAAAATTATTTCTAGAGGGGAATTGTTA

TCCGCTCACAATTCCCCTATAGTGAGTCGTATTAATTTC

GCGGGTTATAAAAGCTCTTCGTACG

sacB/
TGGCGTAATGCAGCAGAAAATGGTCAGAAGAACTCGT
158

Kan-F
CAAGAAG

sacB/
GATAAAATTCGCTAAAAGACATCATCACATATACCTGC
159

Kan-R
CGTTC

WG-F
GAACGTCGTCCGGCTGATGCC
160

WG-R
TGGTATCGGTCTGCGATTCCGAC
161

Example 3
Construction of Plasmid pZG07

Genes eryAII (encoding polyketide synthetase DEBS2 of Streptomyces erythreus, derived from Genbank No.: NC_009142) and eryAIII (encoding polyketide synthetase DEBS3 of Streptomyces erythreus, derived from Genbank No.: NC_009142) were respectively PCR amplified using the genomic DNA of Saccharopolyspora erythraea as the template together with primers eryAII-F and eryAII-R as well as eryAIII-F and eryAIII-R (Table 5), the purified PCR products were respectively double digested with NdeI/HindIII, and then the double-digested PCR products were respectively ligated with T4 DNA ligase to plasmid pET21c subjected to the same digestion, respectively obtaining plasmids pZG05 (containing eryAII) and pZG06 (containing eryAIII); and then, pZG06 was digested with XbaI/EcoRI, the DNA fragment containing eryAIII gene was ligated with T4 DNA ligase to plasmid pZG05 digested with SpeI/EcoRI after being recovered, constructing plasmid pZG07, wherein the schematic diagram of the construction process of the polyketone synthesis gene cluster plasmid pZG07 was as shown in FIG. 3.

TABLE 5

Primers used in this example and the

corresponding base sequences thereof

SEQ

ID

Primer
Base sequence
NO:

eryA
GGAATTCCATATGGTGACTGACAGCGAGAAGGTGGC
162

II-F

eryA
CTAGAGAATTCCTAGTCTACAGGTCCTCTCCCCCGCC
163

II-R

eryA
GGAATTCCATATGATGAGCGGTGACAACGGCATGA
164

III-F

eryA
GATGAATTCTCATGAATTCCCTCCGCCCAGC
165

III-R

Example 4
Construction of Plasmid pZG08

Gene pccB (encoding propionyl-CoA carboxylase β-CT subunit, derived from Genbank No.: NC_003888.3) and gene accA (encoding propionyl-CoA carboxylase a-CT subunit, derived from Genbank No.: NC_003888.3) were respectively amplified using the genomic DNA of Streptomyces coelicolor as the template together with primers pccB-F and pccB-R as well as accA2-F and accA2-R (Table 6), the purified PCR products were respectively double digested with NcoI/EcoRI, and then the double-digested PCR products were respectively ligated with T4 DNA ligase to the pET28a plasmid double digested with NcoI/EcoRI, constructing plasmids pZG01 and pZG02; and then, pZG02 was double digested with XbaI/EcoRI, the DNA fragment containing the gene accA2 was recovered and ligated with T4 DNA ligase to the pZG01 plasmid double digested with SpeI/EcoRI, obtaining plasmid pZG03.

Gene eryAI (encoding polyketide synthetase DEBS1 of Streptomyces erythreus, Genbank No.: NC_009142) was PCR amplified using the genomic DNA of Saccharopolyspora erythraea as the template together with primers eryAI-F and eryAI-R, the purified PCR product was double digested with NdeI/EcoRI and then ligated with T4 DNA ligase to plasmid pET28a double digested with NdeI/EcoRI, constructing plasmid pZG04;

pZG04 was linearized with Bg/II and the linearized fragment was recovered, the ends of the linearized fragment were then digested with exonuclease I to convert the cohesive ends resulting from the digestion of Bg/II to blunt ends, after which the linearized fragment was recovered again, and finally the fragment was digested with HindIII to recover the eryAI gene fragment; and

pZG03 was first linearized with EcoRI and recovered, the cohesive ends of EcoRI were then converted to blunt ends by the use of exonuclease I and recovered, and finally the linearized pZG03 was digested with HindIII and recovered.

The above recovered pZG03 was ligated to the eryAI gene fragment, constructing plasmid pZG08, wherein the schematic diagram of the construction process of the plasmid pZG08 was as shown in FIG. 4.

TABLE 6

Primers used in this example and the

corresponding base sequences thereof

SEQ

ID

Primer
Base sequence
NO:

eryA
GGAATTCCATATGGTGGCGGACCTGTCAAAGCTCTC
166

I-F

eryA
GATGAATTCTCAATCGCCGTCGAGCTCCCG
167

I-R

pccB-
GGAATTCCATATGATGGGCAGCAGCCATCATCATC
168

F

pccB-
CTAGACTAGTTTACAGGGGGATGTTGCCGTG
169

R

accA2-
CATGCCATGGATATGCGCAAGGTGCTCATCGC
139

F

accA2-
GATGAATTCGAATTCTCAGTCCTTGATCTCGCAGATGGC
27

R

Example 5
Construction of an Engineered Strain of the Polyketide 6-dEB and its Fermentation Culture in a 5 L Tank

The plasmids pZG07 and pZG08 were co-transformed into the above-obtained host strain E. coli WG for heterologously synthesizing a polyketide, obtaining an engineered strain E. coli WG (pZG07/pZG08) (for producing 6-dEB, an erythromycin precursor) that is capable of effectively synthesizing the polyketide. Single colonies were picked into 2 ml of LB medium supplemented with 100 mg/L of carbenicillin and 50 mg/L of kanamycin, and the mixture was cultured at 220 rpm, 37° C. overnight, giving primary seeds.

Then, the above-obtained primary seeds were inoculated into a 500 ml shake flask containing 50 ml of LB medium supplemented with 100 mg/L of carbenicillin and 50 mg/L of kanamycin at an inoculum size of 1%, and the mixture was cultured at 220 rpm, 37° C. until the OD600 was about 1, giving secondary seeds.

Then, the resulting secondary seeds were inoculated into a 5 L tank containing 4 L of fermentation medium supplemented with 100 mg/L of carbenicillin and 50 mg/L of kanamycin at an inoculum size of 1%, IPTG with a final concentration of 0.1 mM and 20 mM of sodium propionate were added at the same time, and the fermentation was completed after inducing and culturing the mixture at 22° C., 250 rpm for 5 days.

Example 6
Preparation of 6-dEB and HPLC-ELSD Analysis and Detection

The fermentation broth of Example 5 was extracted three times with an equal volume of ethyl acetate and concentrated under reduced pressure to give a crude extract. The crude extract was eluted in a reversed phase C-18 column using methanol-water system, wherein the ratios of methanol were 30%, 50%, 70% and 100%, respectively. The isolated fractions were analyzed using Ultimate 3000 analytical HPLC. The analysis results showed that the product 6-dEB was mainly present in the fraction with a methanol ratio of 70%, and the HPLC analysis was shown in FIG. 5.

The above crude fraction containing 6-dEB was isolated by a reverse phase C-18 column and analyzed and prepared by HPLC-ELSD to give pure 6-dEB. The HPLC-ELSD detection and preparation conditions were as follows. The fraction eluted with 70% methanol was isolated and prepared by Ultimate 3000 preparative HPLC, wherein the chromatographic column model was: TSK-100V, 5 μm, 19*150 mm, flow rate 15 ml/min, and mobile phase 50% acetonitrile/water system for isocratic elution. The ELSD detector conditions were as follows: evaporative light scattering detector drift tube temperature: 95° C.; gas flow rate: 1.6 l/min; and gain: 16. Retention time t_R: 10.3 min.

The pure 6-dEB was verified by nuclear magnetic analysis. The hydrogen spectrum was shown in FIG. 6. It can be seen from the figure that the chemical shift of H spectrum of the prepared pure product was consistent with that reported in the literature (Xin Gao, Sang Kook Woo, Michael J. Krische, Total Synthesis of 6-Deoxyerythronolide B via C—C Bond-Forming Transfer Hydrogenation, J. Am. Chem. Soc. 2013, 135, 4223-4226), determining that this compound is 6-dEB.

The prepared standard was formulated as 40 mg/L of methanol solution and analyzed by Ultimate 3000 analytical HPLC, with conditions as follows: chromatographic column TSK-100V, 5 μm, 4.6*150 mm; flow rate 1 ml/min; and mobile phase acetonitrile/water, with 50% of acetonitrile, for gradient elution. ELSD was used as the detector and the conditions were as follows: evaporative light scattering detector drift tube temperature: 95° C.; gas flow rate: 1.6 l/min; and gain: 16. It can be seen from FIG. 7 that the pure 6-dEB prepared had a very high purity, with the purity up to 98% or more.

Example 7
Transformation and Fermentation of sRNA Plasmids

The various sRNA plasmids expressed in Example 1 (using pACYCDuet-1 (purchased from Novagen) as a blank control) were respectively transformed into the host cells E. coli WG (pZG07/pZG08) (for producing 6-dEB, an erythromycin precursor), single colonies were respectively picked into 2 ml of LB medium containing carbenicillin (100 mg/L), kanamycin (50 mg/L) and chloramphenicol (34 mg/L), and the mixture was cultured at 37° C., 250 rpm/min overnight for 12 h as seeds for shaker fermentation culture.

The above seeds were inoculated in a 100 ml shake flask containing 10 ml of 6-dEB fermentation medium (containing carbenicillin, kanamycin and chloramphenicol antibiotics) at an inoculum size of 1%, and sodium propionate precursor with a final concentration of 20 mM and 100 mM of isopropyl-β-D-thiogalactopyranoside (IPTG) were added at the same time for initial induction, wherein each sample was run three times in parallel. The shake flask was placed in a shaker at 22° C., 250 rpm/min to ferment for 5 days. After the fermentation was completed, the fermentation broth was poured into a 10 ml centrifuge tube and stored at −20° C. for subsequent detection and analysis.

Example 8
Analysis and Detection of 6-dEB of the Fermentation Broth in Example 7

The fermentation broth of Example 7 was analyzed and detected by a high performance liquid chromatography-evaporative light scattering detector (HPLC-ELSD). The conditions were as follows: chromatographic column TSK-100V, 5 μm, 4.6*150 mm; flow rate 1 ml/min; and mobile phase acetonitrile/water, with 50% of acetonitrile, for isocratic elution. ELSD was used as the detector and the conditions were as follows: evaporative light scattering detector drift tube temperature: 95° C.; gas flow rate: 1.6 l/min; and gain: 16.

The results of the effects of attenuation of different genes on the synthesis of 6-dEB were shown in Table 7 (the yield of 6-dEB in the control group E. coli WG (pZG07/pZG08/pACYCDunet-1) was 100%). As can be seen from Table 7: attenuation of each of these key target genes by the use of sRNA was beneficial to the synthesis of the target product 6-dEB. For example, the key target gene regulated by the strain E. coli WG (pZG07/pZG08/pSJ39) was sucC (synthetase: succinyl-CoA synthetase, β subunit). Compared with the control group E. coli WG (pZG07/pZG08/pACYCDunet-1), attenuation of sucC may allow the yield increase rate of 6-dEB synthesized by the host to reach 63.2%. E. coli WG (pZG07/pZG08/pSJ130) may increase the highest yield, the key target gene regulated thereby is talB (transaldolase), and attenuation of talB may allow the yield increase rate of 6-dEB synthesized by the host to reach 1008.81%.

Using an sRNA method to regulate the metabolic network of the chassis cells of E. coli, the heterologous synthesis of the polyketide can be significantly improved by attenuating these genes. Targets through attenuating which to increase the yield of the polyketide by 20% or more were as follows: ybiW, fadB, ackA, pta, yjiM, dhaK2, ptsH, ptsI, frdD, frdA, sdhA, sucC, sucD, glcE, lsrC, rpiA, serC, talA, talB, zwf, pyrI, cysQ, gmk, guaB, pyrH and hpt.

TABLE 7

Effect of sRNA interference on the synthesis of 6-dEB by heterologous

host E. coli

Target attenuated by
Yield of 6-dEB

an sRNA plasmid
(mg/L)
Yield increase rate of 6-dEB (%)

sucC
23.34
63.2406

yjiM
21.97
53.6493

frdD
21.33
49.1429

lsrC
20.95
46.5013

glcE
20.02
39.9762

ybiW
19.97
39.6476

sdhA
19.82
38.5955

ptsH
19.66
37.4517

dhaK2
19.11
33.6389

sucD
19.11
33.6232

frdA
18.61
30.1259

ptsI
18.58
29.9126

fadB
18.25
27.6126

ackA
17.76
24.169

serC
17.74
24.0419

rpiA
17.50
22.3742

Pta
17.18
20.1588

pflB
17.12
19.7255

dhaK1
17.05
19.2565

serB
16.81
17.5799

lueD
16.59
16.0076

sdhB
16.52
15.5126

lueC
16.38
14.5198

fsaA
16.30
13.9704

tdcE
16.09
12.5035

sdhD
16.08
12.4802

fadJ
15.98
11.7827

rpiB
15.88
11.0452

Pgi
15.75
10.1108

glcF
15.67
9.57697

scpB
15.59
9.00411

tdcD
15.57
8.85684

scpA
15.51
8.47025

sdhC
15.51
8.46854

dhaH
15.50
8.36834

Ppk
15.27
6.76265

lpdA
15.27
6.75137

cyoA
15.18
6.12731

aceF
15.12
5.72787

PaaF
15.05
5.26518

purT
15.02
5.00937

gdhA
15.01
4.97136

agaW
14.82
3.62747

sera
14.62
2.24778

yaeR
14.56
1.84435

tnaA
14.56
1.81189

pflD
14.41
0.77645

hemN
14.35
0.37817

cyoB
14.35
0.3568

talB
158.57
1008.881

talA
121.34
748.5315

zwf
93.06
550.7692

pgl
77.56
442.3776

rpe
63.46
343.7762

tktA
60.36
322.0979

gnd
56.41
294.4755

ulaE
50.83
255.4545

tktB
47.67
233.3566

yieK
47.44
231.7483

guaB
127.21
789.5804

hpt
110.28
671.1888

cysQ
108.14
656.2238

pyrI
97.03
578.5315

pyrH
95.0
564.3357

gmk
94.32
559.5804

pyrF
89.30
524.4755

guaA
86.37
503.986

pyrE
85.24
496.0839

purH
77.85
444.4056

ndk
77.678
443.2028

pyrB
75.08
425.035

pyrC
54.10
278.3217

pACYCDuent-1
14.30
0

(control)

Example 9
Combined Attenuation Through Co-Transformation of sRNA Plasmids Further Improves the Yield of the Polyketide 6-dEB

As can be seen from the data in Example 8: targets after attenuating which to increase the yield of the polyketide by 20% or more, ybiW, fadB, ackA, pta, yjiM, dhaK2, ptsH, ptsI, frdD, frdA, sdhA, sucC, sucD, glcE, lsrC, rpiA and serC, were selected, chloramphenicol resistance in these attenuated plasmids above was replaced with apramycin resistance for resistance screening of subsequent combination-co-transformation.

Construction of a plasmid with its resistance replaced was based on the POE-PCR technical method (You et al., Simple cloning via direct transformation of PCR product (DNA Multimer) to Escherichia coli and Bacillus subtilis. Appl Environ Microbiol, 78(5): 1593-1595), by taking the replacement of the resistance of the control plasmid pACYCDuent-1 as an example, the apramycin resistance gene of the pKC1139 plasmid was first directly amplified by PCR using pKC1139 (a universal plasmid for Streptomyces) as the template together with the Aparamycin-F and Aparamycin-R primers in Table 8 and the PCR conditions (see Table 9); and sequences except for the chloramphenicol resistance gene of the pACYCDuent-1 plasmid were amplified by PCR using pACYCDuent-1 as the template together with the sRNA-Aparamycin-F and sRNA-Aparamycin-R primers in Table 8 and the PCR conditions. Then, PCR was carried out using the PCR conditions in Table 9 (note: primers were not added, and the templates were the apramycin resistance gene and the pACYCDuent-1 without the chloramphenicol resistance gene amplified in the first step, each 1 μl), this PCR product was directly transformed into DH10B after being recovered by a PCR cleaning and recovering kit, and the mixture was plated on an LB solid medium plate containing 50 mg/L of apramycin and cultured overnight. Single colonies were picked into 2 ml of LB medium containing 50 mg/L of apramycin, the mixture was cultured at 220 rpm, 37° C. overnight, and a plasmid extraction kit was used to extract a plasmid, obtaining plasmid pSJ77.

TABLE 8

Primer information and PCR conditions

SEQ

Primer

ID

name
Sequence (5′→3′)
NO:

Aparamycin-
caccaataactgccttaaaaaaaGCCAATCGACT
170

F
GGCGAGCGG

Aparamycin-
tcgagattttcaggagctaaggaagctaaaATGC
171

R
AATACGAATGGCGAAA

sRNA-
ccgctcgccagtcgattggctttttttaaggcag
172

Aparamycin-
ttattggtg

F

sRNA-
tttcgccattcgtattgcattttagcttccttag
173

Aparamycin-
ctcctgaaaatctcga

R

TABLE 9

PCR conditions

Name
PCR conditions

System
5x PS buffer: 5 μl; dNTP: 2.5 μl; template: 0.3 μl; upstream

and downstream primers: each 0.5 μl; PrimeStar enzyme:

0.25 μl; ddH₂O: to make up to 25 μl;

Program
pre-denaturation at 98° C.: 3 min; 30 cycles: denaturation at

98° C.: 10 s, annealing at 55° C.: 15 s, and extending at

72° C.: 3 min 10 s; 72° C.: 10 min; maintaining at 16° C.

The replacement of the resistance of the remaining sRNA-expressing plasmids was the same as above by using the same primers and PCR conditions to replace chloramphenicol resistance in a plasmid with apramycin resistance, and the information of each sRNA plasmid was as shown in Table 10.

TABLE 10

sRNA plasmid information

Name
Plasmid information
Resistance

pSJ77
pACYCDuet-1-derived plasmid, with
apramycin

chloramphenicol resistance changed into apramycin

resistance, an sRNA empty plasmid

pSJ78
pSJ04-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with ybiW attenuated

pSJ79
pSJ10-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with fadB attenuated

pSJ80
pSJ11-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with ackA attenuated

pSJ81
pSJ12-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with pta attenuated

pSJ82
pSJ15-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with yjiM attenuated

pSJ83
pSJ18-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with dhaK2 attenuated

pSJ84
pSJ20-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with ptsH attenuated

pSJ85
pSJ21-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with ptsI attenuated

pSJ86
pSJ30-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with frdD attenuated

pSJ87
pSJ33-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with frdA attenuated

pSJ88
pSJ35-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with sdhA attenuated

pSJ89
pSJ39-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with sucC attenuated

pSJ90
pSJ40-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with sucD attenuated

pSJ92
pS44-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with glcE attenuated

pSJ93
pSJ53-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with lsrC attenuated

pSJ94
pJF667-derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with rpiA attenuated

pSJ95
pJF672derived plasmid, with chloramphenicol
apramycin

resistance changed into apramycin resistance,

expresses an sRNA with serC attenuated

The sRNA-expressing plasmids (using pSJ77 as a blank control) constructed above and the sRNA-expressing plasmids constructed in Example 1 for increasing the relative yield by 20% were combined in pairs, and co-transformed in the host cells E. coli WG (pZG07/pZG08) (for producing 6-dEB, an erythromycin precursor), using the fermentation method in Example 7 and the analysis and detection of 6-dEB in Example 8.

In the sRNA combined fermentation experiment, the yield of 6-dEB in the control group E. coli WG (pZG07/pZG08/pSJ39/pSJ77) was 100%, and the yield of the polyketide 6-dEB was further increased by attenuating the key target genes in combination.

The experimental results of the effect of combined sRNA interference on the synthesis of 6-dEB by heterologous host E. coli were as shown in Table 11.

TABLE 11

Effect of combined sRNA interference on the synthesis of 6-dEB by

heterologous host E. coli

Target

Relative

Name of plasmid
attenuated by an
Yield of 6-dEB
yield increase

combination
sRNA plasmid
(mg/L)
rate of 6-dEB (%)

pSJ30 + pSJ39
frdD + sucC
28.73
24.36

pSJ53 + pSJ30
lsrC + frdD
27.11
17.36

pSJ53 + pSJ39
lsrC + sucC
24.15
4.53

pSJ30 + pSJ94
frdD + rpiA
23.24
0.59

pSJ39 + pSJ77
sucC +
23.10
0.00

pACYCDuent-1

(control)

pSJ30 + pSJ88
frdD + sdhA
23.07
−0.14

pSJ30 + pSJ84
frdD + ptsH
22.54
−2.43

pSJ30 + pSJ82
frdD + yjiM
22.33
−3.33

pSJ30 + pSJ81
frdD + pta
22.20
−3.89

pSJ53 + pSJ80
lsrC + ackA
22.00
−4.75

pSJ30 + pSJ39
frdD + sucD
21.90
−5.20

pSJ30 + pSJ79
frdD + fadB
21.87
−5.34

pSJ53 + pSJ94
lsrC + rpiA
21.42
−7.26

pSJ30 + pSJ80
frdD + ackA
21.08
−8.76

pSJ53 + pSJ92
lsrC + glcE
20.87
−9.65

pSJ53 + pSJ79
lsrC + fadB
20.64
−10.63

pSJ53 + pSJ85
lsrC + ptsI
20.63
−10.68

pSJ30 + pSJ83
frdD + dhaK2
20.55
−11.06

pSJ53 + pSJ81
lsrC + pta
20.12
−12.91

pSJ53 + pSJ39
lsrC + sucC
20.09
−13.02

pSJ30 + pSJ85
frdD + ptsI
19.67
−14.86

pSJ30 + pSJ78
frdD + ybiW
19.56
−15.34

pSJ53 + pSJ87
lsrC + frdA
19.34
−16.28

pSJ53 + pSJ90
lsrC + sucD
18.87
−18.33

pSJ30 + pSJ83
lsrC + dhaK2
18.37
−20.48

pSJ53 + pSJ78
lsrC + ybiW
17.81
−22.91

pSJ53 + pSJ88
lsrC + sdhA
17.70
−23.36

pSJ53 + pSJ95
lsrC + serC
17.46
−24.41

pSJ30 + pSJ87
frdD + frdA
17.24
−25.37

pSJ53 + pSJ82
lsrC + yjiM
16.29
−29.46

pSJ53 + pSJ84
lsrC + ptsH
13.94
−39.65

pSJ30 + pSJ95
frdD + serC
12.28
−46.83

The experimental results showed that although most combined attenuations cannot effectively improve the synthesis of the polyketide, combined attenuation of frdD and sucC may further increase the yield of 6-dEB by 24% or more compared with the yield by attenuating sucC alone, and attenuating lsrC and frdD simultaneously may further increase the yield of 6-dEB by 17% or more.

Example 10
sRNA Plasmids with Two Targets Attenuated Further Increase the Yield of the Polyketide 6-dEB

It can be seen according to the data in Example 8: targets attenuated were as follows that increased the yield of the polyketide by more than 550%: genes talA, talB and zwf for nucleotide synthesis and other metabolism modules and genes pyrI, cysQ, gmk, guaB, pyrH and hpt for pentose phosphate and glyoxylate pathway modules, and the effect of the simultaneous attenuation of the targets of the two modules on the yield of the polyketide 6-dEB synthesized was investigated.

sRNA plasmids with two targets attenuated were all constructed by a digestion and series connection method. Taking the construction of pSJ333 as an example: a ta1B-targeting sRNA skeleton was amplified using pSJ130 as the template and sRNA-F/R as the primers (Table 12), wherein the PCR conditions were the same as that in Table 9 of Example 9. The PCR product was digested with BamHI and HindIII after being cleaned and recovered; and pSJ129 as the vector was digested with BglII and HindIII at the same time and cleaned and recovered. The above PCR digested-product was ligated with T4 DNA ligase to the double-digested pSJ129 product, obtaining plasmid pSJ333. The remaining plasmids were obtained in the same way, obtaining plasmids pSJ404-pSJ421 finally, and the plasmid information was as shown in Table 13.

TABLE 12

Primer information

Primer

name
Sequence (5′→3′)

sRNA-F
CGGGATCCTAACACCGTGCGTGTTGACTATTTTA

sRNA-R
CCCAAGCTTAGATCTACTAGTTATAAACGCAGAAAGG

TABLE 13

Combined sRNA plasmid information

Target regulated

(attenuated) by sRNA

Name
technology
Resistance

pSJ333
talA + talB
chloramphenicol

pSJ334
cysQ + guaB
chloramphenicol

pSJ404
talA + pyrI
chloramphenicol

pSJ405
talA + cysQ
chloramphenicol

pSJ406
talA + gmk
chloramphenicol

pSJ407
talA + guaB
chloramphenicol

pSJ408
talA + pyrH
chloramphenicol

pSJ409
talA + hpt
chloramphenicol

pSJ410
talB + pyrI
chloramphenicol

pSJ411
talB + cysQ
chloramphenicol

pSJ412
talB + gmk
chloramphenicol

pSJ413
talB + guaB
chloramphenicol

pSJ414
talB + pyrH
chloramphenicol

pSJ415
talB + hpt
chloramphenicol

pSJ416
zwf + pyrI
chloramphenicol

pSJ417
zwf + cysQ
chloramphenicol

pSJ418
zwf + gmk
chloramphenicol

pSJ419
zwf + guaB
chloramphenicol

pSJ420
zwf + pyrH
chloramphenicol

pSJ421
zwf + hpt
chloramphenicol

The combined sRNA-expressing plasmids (using pACYCDuent-1 as a blank control) constructed above were transformed in the host cells E. coli WG (pZG07/pZG08) (for producing 6-dEB, an erythromycin precursor), using the fermentation method in Example 7 and the analysis and detection of 6-dEB in Example 8.

The experimental results of the effect of combined sRNA interference on the synthesis of 6-dEB by heterologous host E. coli were as shown in Table 14 and FIG. 8. The experiment showed that although all the combined attenuations can effectively improve the synthesis of the polyketide, only combined attenuations of talA+guaB and zwf+guaB may further increase the yield of 6-dEB by 32% or more compared with the yield by attenuating talB alone and by 1300% or more compared with the yield of the control group, enabling the shake flask yield of 6-dEB to reach 210 mg/L or more.

TABLE 14

Effect of combined sRNA interference on the synthesis of 6-dEB by

heterologous host E. coli

Target

Relative

attenuated by an
Yield of 6-dEB
yield increase

Plasmid name
sRNA plasmid
(mg/L)
rate of 6-dEB (%)

pACYCDuent-1
control
14.30
0.00

pSJ404
talA + pyrI
135.10
844.76

pSJ405
talA + cysQ
128.87
801.19

pSJ406
talA + gmk
117.09
718.81

pSJ407
talA + guaB
209.38
1364.20

pSJ408
talA + pyrH
153.30
972.03

pSJ409
talA + hpt
118.84
731.05

pSJ410
talB + pyrI
145.38
916.64

pSJ411
talB + cysQ
120.11
739.93

pSJ412
talB + gmk
138.00
865.03

pSJ413
talB + guaB
60.05
319.93

pSJ414
talB + pyrH
149.79
947.48

pSJ415
talB + hpt
100.32
601.54

pSJ416
zwf + pyrI
152.75
968.18

pSJ417
zwf + cysQ
130.45
812.24

pSJ418
zwf + gmk
119.39
734.90

pSJ419
zwf + guaB
210.42
1371.47

pSJ420
zwf + pyrH
75.35
426.92

All the documents mentioned in the present invention are incorporated by reference in the present application, as if each document is alone incorporated by reference. In addition, it should be understood that after reading the above-mentioned teaching contents of the present invention, those skilled in the art would be able to make various modifications or amendments to the present invention, and these equivalent forms likewise fall within the scope defined by the appended claims of the present application.

Claims

1. A method for increasing the yield of heterologous synthesis of a polyketide 6-deoxyerythronolide B by 20% or more in an E. coli compared to unattenuated E. coli wherein the method comprises: (1) attenuating an expression of a target gene in the E. coli for synthesizing the polyketide 6-deoxyerythronolide B;wherein, the target gene is selected from:(a) a gene for nucleotide synthesis and other metabolism modules: phosphoribosyl glycinamide formyltransferase 2 purT, autoinducer-2ABC transporter lsrC, coproporphyrinogen III dehydrogenase hemN, glucose 6-phosphate-1-dehydrogenase zwf, 6-phosphogluconolactonase pgl, 6-phosphogluconate dehydrogenase gnd, ribulose-5-phosphate 3-epimerase rpe, transaldolase A talA, transaldolase talB, transketolase I tktA, transketolase II tktB, L-xylulose 5-phosphate 3-epimerase ulaE or predicted 6-phosphogluconolactonase yieK;(b) a gene for pentose phosphate and glyoxylate pathway modules: predicted lyase yaeR, ribose-5-phosphate isomerase A rpiA, allose-6-phosphate isomerase/ribose-5-phosphate isomerase B rpiB, AICAR transformylase purH, aspartate carbamoyltransferase, catalytic subunit pyrB, aspartate carbamoyltransferase, regulatory subunit pyrI, adenosine-3′(2′),5′-bisphosphate nucleotidase cysQ, dihydroorotase pyrC, guanylate kinase gmk, GMP synthetase guaA, IMP dehydrogenase guaB, nucleoside diphosphate kinase ndk, orotidine-5′-phosphate decarboxylase pyrF, orotate phosphoribosyltransferase pyrE, UMP kinase pyrH or hypoxanthine phosphoribosyltransferase hpt;(c) a gene for TCA cycle and oxidative phosphorylation modules: fumarate reductase frdD, fumarate reductase, a subunit frdA, succinate dehydrogenase A sdhA, succinate dehydrogenase B sdhB, succinate dehydrogenase C sdhC, succinate dehydrogenase D sdhD, succinyl-CoA synthetase, β subunit sucC, succinyl-CoA synthetase sucD, cytochrome bo terminal oxidase subunit II cyoA or cytochrome bo terminal oxidase subunit I cyoB;(d) a gene for carbohydrate metabolism module: pyruvate dehydrogenase accF, phosphoglucose isomerase pgi, lipoamide dehydrogenase lpdA, polyphosphate kinase ppk, HPr protein of phosphoenolpyruvate-sugar phosphotransferase system ptsH, PTSI protein of phosphoenolpyruvate-sugar phosphotransferase system ptsI, glycolateoxidase, predicted iron-sulfur subunit glcF, glycolate oxidase, FAD-binding subunit glcE, fructose 6-phosphate aldolase 1 fsaA or N-acetylgalactosameine-specific IIC component 2 of PTS system agaW;(e) a gene for 6-dEB precursor metabolism module: methylmalonyl-CoA mutase scpA, propionate kinase tdcD, 2-ketobutyrate formatelyase/pyruvate formatelyase 4, inactive tdcE, pyruvate formatelyase pfiB, formate acetyltransferase 2 pfD, predicted 2,3-dehydroadipyl-CoA hydratase PaaF, acetate kinase ackA, phosphate acetyltransferase/phosphate propionyltransferase pta or pyruvate formatelyase ybiW;(f) a gene for fatty acid metabolism module: FadJ component of anaerobic fatty acid oxidation complex fadJ, fatty acid oxidation complex, a component fadB, dihydroxyacetone kinase subunit K dhaK1, dihydroxyacetone kinase dhaK2 or dihydroxyacetone kinase subunit M dhaH;(g) a gene for amino acid and protein synthetic metabolism modules: isopropylmalate isomerase leuC, isopropylmalate isomerase lcuD, 3-phosphoserine/phosphohydroxythreonine aminotransferase scrC, phosphoserine phosphatase scrB, D-3-phosphoglycerate dehydrogenase/a-ketoglutarate reductase serA, glutamate dehydrogenase gdhA or tryptophanase/L-cysteine desulhydrase tnaA; or(h) the combination of frdD+sucC, the combination of IsrC+frdD, the combination of IsrC+sucC, the combination of frdD+rpiA, the combination of talA+guaB or the combination of zwf+guaB; and(2) culturing the E. coli prepared in step (1), thereby synthesizing the polyketide 6-deoxyerythronolide,wherein attenuating the expression of the target gene in the E. coli comprises introducing an interfering molecule that inhibits the expression of the target gene or knocking out the target gene,wherein the interfering molecule that inhibits the expression of the target gene is directed to:
2. The method of claim 1, wherein in (1), the target gene is selected from: (a) a gene for nucleotide synthesis and other metabolism modules: lsrC, zwf, pgl, gnd, rpe, talA, talB, tktA, tktB, ulaE or yieK;(b) a gene for pentose phosphate and glyoxylate pathway modules: rpiA, purH, pyrB, pyrI, cysQ, pyrC, gmk, guaA, guaB, ndk, pyrF, pyrE, pyrH or hpt;(c) a gene for TCA cycle and oxidative phosphorylation modules: frdD, frdA, sdhA, sucC or sucD;(d) a gene for carbohydrate metabolism module: ptsH, ptsI or glcE;(e) a gene for 6-dEB precursor metabolism module: yjiM, ackA, pta or ybiW;(f) a gene for fatty acid metabolism module: fadB or dhaK2;(g) a gene for amino acid and protein synthetic metabolism modules: serC; or(h) the combination of frdD+sucC, the combination of lsrC+frdD, the combination of lsrC+sucC, the combination of talA+guaB or the combination of zwf+guaB.
3. The method of claim 1, wherein the interfering molecule that inhibits the expression of the target gene is an siRNA.
4. The method of claim 3, wherein the siRNA comprises the following structure: a promoter, a target gene-inhibiting molecule and a terminator.
5. The method of claim 3, wherein the siRNA is included in an expression vector.
6. The method of claim 1, wherein the E. coli is capable of synthesizing the polyketide 6-deoxyerythronolide B.
7. The method of claim 6, wherein in the E. coli, the operon for propionic acid metabolism is knocked out and phosphopantetheinyl transferase gene sfp is integrated into the knockout site; or the operon for propionic acid metabolism is directly knocked out and sfp is incorporated into any non-essential gene or a non-functional DNA sequence region in the genome of the E. coli.
8. The method of claim 7, wherein the E. coli is transformed with a gene encoding polyketide synthetase DEBS2 of Streptomyces erythreus, a gene encoding polyketide synthetase DEBS3 of Streptomyces erythreus, a gene encoding propionyl-CoA carboxylase β-CT subunit, a gene encoding propionyl-CoA carboxylase α-CT subunit and a gene encoding polyketide synthetase DEBS1 of Streptomyces erythreus.
9. The method of claim 4, wherein the structure further comprises a micF sequence between the target gene-inhibiting molecule and the terminator.
10. The method of claim 1, wherein the interfering molecule that inhibits the expression of the target gene further comprises: a sequence shown in SEQ ID NO: 2 in tdcD or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 4 in scpA or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 5 in ybiW or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 6 in pflB or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 7 in tdcE or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 8 in pflD or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 9 in paaF or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 10 in fadJ or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 11 in fadB or a full complementary sequence thereof, ora sequence shown in SEQ ID NO: 12 in ackA or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 13 in pta or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 14 in leuD or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 15 in leuC or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 17 in purT or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 18 in dhaK1 or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 20 in dhaH or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 21 in ptsH or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 22 in ptsI or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 23 in fsaA or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 24 in ppk or a full complementary sequence thereof, ora sequence shown in SEQ ID NO: 25 in aceF or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 26 in cyoA or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 30 in frdD or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 31 in frdA or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 32 in pgi or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 33 in sdhA or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 34 in sdhB or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 35 in sdhC or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 36 in sdhD or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 38 in sucD or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 39 in tnaA or a full complementary sequence thereof, ora sequence shown in SEQ ID NO: 40 in glcF or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 42 in yaeR or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 43 in lsrC or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 44 in hemN or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 45 in agaW or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 46 in gdhA or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 47 in cyoB or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 48 in rpiA or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 49 in rpiB or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 50 in lpdA or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 28 in serB or a full complementary sequence thereof, ora sequence shown in SEQ ID NO: 29 in serA or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 175 in pgl or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 176 in gnd or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 177 in rpe or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 180 in tktA or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 181 in tktB or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 182 in ulaE or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 183 in yieK or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 184 in purH or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 185 in pyrB or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 186 in pyrI or a full complementary sequence thereof, ora sequence shown in SEQ ID NO: 187 in cysQ or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 188 in pyrC or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 189 in gmk or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 190 in guaA or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 192 in ndk or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 193 in pyrF or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 194 in pyre or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 195 in pyrH or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 196 in hpt or a full complementary sequence thereof.

Priority Claims (1)

Number	Date	Country	Kind
2014 1 0338738	Jul 2014	CN	national

PCT Information

Filing Document	Filing Date	Country	Kind
PCT/CN2015/079161	5/18/2015	WO	00

Publishing Document	Publishing Date	Country	Kind
WO2016/008332	1/21/2016	WO	A

Foreign Referenced Citations (3)

Number	Date	Country
101215557	Jul 2008	CN
101255413	Sep 2008	CN
103849642	Jun 2014	CN

Non-Patent Literature Citations (5)

Entry
Kizer et al. Application of Functional Genomics to Pathway Optimization for Increased Isoprenoid Production. Appl. Environ. Microbiol. 74:3229-3241, 2008.
Murli et al. Metabolic engineering of Escherichia coli for improved 6-deoxyerythronolide B production. J Ind Microbiol Biotechnol (2003) 30: 500-509.
International Search Report for PCT/CN2015/079161 (dated Jan. 21, 2016).
Zhang, Li-hua et al., “Cloning and Expression of Polyketide Synthases Gene eryA III of Saccharopolyspora etythraea in Escherichia coli”, Letter in Biotechnology, vol. 21, No. 6, Nov. 30, 2010, ISSN: 1009-0002, pp. 794-797.
Reeves, Andrew R. et al., “Engineering precursor flow for increased erythromycin production in Aeromicrobium erythreum”, Metabolic Engineering, vol. 6, issue 4, Dec. 31, 2004, ISSN: 1096-7176, pp. 300-312.

Related Publications (1)

	Number	Date	Country
	20180016585 A1	Jan 2018	US

Method for improving heterologous synthesis of Escherichia coli into polyketides and use of same

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications

Term Extension